Estscin inhibitors

JP2026519061APending Publication Date: 2026-06-11ベイジン ダブル-クレーン ルーンチャン テクノロジー カンパニー リミテッド
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
ベイジン ダブル-クレーン ルーンチャン テクノロジー カンパニー リミテッド
Filing Date
2024-05-24
Publication Date
2026-06-11

Smart Images

  • Figure 2026519061000001_ABST
    Figure 2026519061000001_ABST
Patent Text Reader

Abstract

The present invention relates to a fascin inhibitor represented by formula (I), its stereoisomers, pharmaceutically acceptable salts thereof or pharmaceutically acceptable salts of its stereoisomers, pharmaceutical compositions thereof, and their use. [Formula 1] JPEG2026519061000354.jpg55166
Need to check novelty before this filing date? Find Prior Art

Claims

1. A compound represented by formula (I), its stereoisomer, its tautomer, its atropisomer, its pharmaceutically acceptable salt, its pharmaceutically acceptable salt of its stereoisomer, its pharmaceutically acceptable salt of its tautomer or its atropisomer. 【Chemistry 1】 (however, X １ is N or CR ３ Selected from, R １ is hydrogen, halogen, -C １～１０ alkyl group, -C ２～６ alkenyl group, -C ２～６ alkynyl group, halogenated C １～１０ alkyl group, -C １～１０ alkoxy group, halogenated C １～１０ alkoxy group, -CN, -OR １２ , -NR １３ R １４ , -SR １５ , -C(=O)R １６ , -C(=O)OR １２ , -OC(=O)R １６ , -C(=O)NR １３ R １４ , -NR １３ C(=O)R １６ , -S(=O)R １７ , -S(=O)OR １２ , -OS(=O)R １７ , -S(=O)NR １３ R １４ , -NR １３ S(=O)R １７ , -S(=O) ２ R １８ , -S(=O) ２ OR １２ , -OS(=O)R １８ , -S(=O) ２ NR １３ R １４ , -NR １３ S(=O) ２ R １８ , -P(=O)(R １９ ) ２ , selected from a 3- to 14-member cycloalkyl group, a 3- to 14-member heterocyclic group, a 6- to 12-member aryl group or a 5- to 14-member heteroaryl group (however, the -C １～１０ alkyl group, -C ２～６ alkenyl group, -C ２～６ alkynyl group, halogenated C １～１０ alkyl group, -C １～１０ alkoxy group, halogenated C １～１０ alkoxy group, a 3- to 14-member cycloalkyl group, a 3- to 14-member heterocyclic group, a 6- to 12-member aryl group or a 5- to 14-member heteroaryl group are each independently halogen, -C １～１０ Alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl group, halogenated C １～１０ Alkoxy group, -CN, oxo, -OR １ｂ , -NR １ｃ R １ｄ , -SR １ｅ , -C(=O)R １ｆ , -C(=O)OR １ｂ , -OC(=O)R １ｆ , -OC(=O)OR １ｂ , -C(=O)NR １ｃ R １ｄ , -OC(=O)NR １ｃ R １ｄ , -C(=NR １ｃ )R １ａ , -C(=NR １ｃ )NR １ｃ R １ｄ , -NR １ｃ C(=NR １ｃ )NR １ｃ R １ｄ , -NR １ｃ C(=O)R １ｆ , -NR １ｃ C(=O)OR １ｂ , -NR １ｃ C(=O)NR １ｃ R １ｄ , -S(=O)R １ｇ , -S(=O)OR １ｂ , -OS(=O)R １ｇ , -OS(=O)OR １ｂ , -S(=O)NR １ｃ R １ｄ , -NR １ｃ S(=O)R １ｇ , -NR １ｃ S(=O)OR １ｂ , -OS(=O)NR １ｃ R １ｄ , -NR １ｃ S(=O)NR １ｃ R １ｄ , -S(=O) ２ R １ｈ , -S(=O) ２ OR １ｂ , -OS (=O) ２ R １ｈ , -OS (=O) ２ OR １ｂ , -S (=O) ２ NR １ｃ R １ｄ , -NR １ｃ S (=O) ２ R １ｈ , -NR １ｃ S (=O) ２ OR １ｂ , -OS (=O) ２ NR １ｃ R １ｄ , -NR １ｃ S (=O) ２ NR １ｃ R １ｄ , -P (=O) (R １ｉ ) ２ (These may be substituted with one or more substituents selected from a 3-14 member cycloalkyl group, a 3-14 member heterocyclic group, a 6-12 member aryl group, or a 5-14 member heteroaryl group.) R ２ is hydrogen, halogen, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy group, -CN, -OR ２２ , -NR ２３ R ２４ , -SR ２５ , -C(=O)R ２６ , -C (=O) OR ２２ -OC(=O)R ２６ , -C(=O)NR ２３ R ２４ , -NR ２３ C(=O)R ２６ , -S(=O)R ２７ , -S (=O) OR ２２ , -OS(=O)R ２７ , -S(=O)NR ２３ R ２４ , -NR ２３ S(=O)R ２７ , -S (=O) ２ R ２８ , -S (=O) ２ OR ２２ , -OS (=O) ２ R ２８ , -S (=O) ２ NR ２３ R ２４ , -NR ２３ S (=O) ２ R ２８ , -P (=O) (R ２９ ) ２ , selected from 3-14 membered cycloalkyl groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups (however, the above-C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy groups, 3-14 membered cycloalkyl groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups are independently halogens and -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -CN, oxo, -OR ２ｂ , -NR ２ｃ R ２ｄ , -SR ２ｅ , -C(=O)R ２ｆ , -C (=O) OR ２ｂ -OC(=O)R ２ｆ , -OC(=O)OR ２ｂ , -C(=O)NR ２ｃ R ２ｄ , -OC(=O)NR ２ｃ R ２ｄ , -C(=NR ２ｃ ) R ２ａ , -C(=NR ２ｃ ) NR ２ｃ R ２ｄ , -NR ２ｃ C (=NR ２ｃ ) NR ２ｃ R ２ｄ , -NR ２ｃ C(=O)R ２ｆ , -NR ２ｃ C (=O) OR ２ｂ , -NR ２ｃ C(=O)NR ２ｃ R ２ｄ , -S(=O)R ２ｇ , -S (=O) OR ２ｂ , -OS(=O)R ２ｇ , -OS(=O)OR ２ｂ , -S(=O)NR ２ｃ R ２ｄ , -NR ２ｃ S(=O)R ２ｇ , -NR ２ｃ S (= O) OR ２ｂ , -OS(=O)NR ２ｃ R ２ｄ , -NR ２ｃ S(=O)NR ２ｃ R ２ｄ , -S (=O) ２ R ２ｈ , -S (=O) ２ OR ２ｂ , -OS (=O) ２ R ２ｈ , -OS (=O) ２ OR ２ｂ , -S (=O) ２ NR ２ｃ R ２ｄ , -NR ２ｃ S (=O) ２ R ２ｈ , -NR ２ｃ S (=O) ２ OR ２ｂ , -OS (=O) ２ NR ２ｃ R ２ｄ , -NR ２ｃ S (=O) ２ NR ２ｃ R ２ｄ , -P (=O) (R ２ｉ ) ２ (These may be substituted with one or more substituents selected from a 3-14 member cycloalkyl group, a 3-14 member heterocyclic group, a 6-12 member aryl group, or a 5-14 member heteroaryl group.) R ３ is hydrogen, halogen, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy group, -CN, -OR ３２ , -NR ３３ R ３４ , -SR ３５ , -C(=O)R ３６ , -C (=O) OR ３２ -OC(=O)R ３６ , -C(=O)NR ３３ R ３４ , -NR ３３ C(=O)R ３６ , -N(R ３３ ) - C (= O) - C ２～６ Alkenyl group -R ３１ , -S(=O)R ３７ , -S (=O) OR ３２ , -OS(=O)R ３７ , -S(=O)NR ３３ R ３４ , -NR ３３ S(=O)R ３７ , -S (=O) ２ R ３８ , -S (=O) ２ OR ３２ , -OS(=O)R ３８ , -S (=O) ２ NR ３３ R ３４ , -NR ３３ S (=O) ２ R ３８ , -P (=O) (R ３９ ) ２ , selected from 3-14 membered cycloalkyl groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups (however, the above-C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy groups, 3-14 membered cycloalkyl groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups are independently halogens and -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy group, -CN, oxo, -OR ３ｂ , -NR ３ｃ R ３ｄ , -SR ３ｅ , -C(=O)R ３ｆ , -C (=O) OR ３ｂ -OC(=O)R ３ｆ , -OC(=O)OR ３ｂ , -C(=O)NR ３ｃ R ３ｄ , -OC(=O)NR ３ｃ R ３ｄ , -C(=NR ３ｃ ) R ３ａ , -C(=NR ３ｃ ) NR ３ｃ R ３ｄ , -NR ３ｃ C (=NR ３ｃ ) NR ３ｃ R ３ｄ , -NR ３ｃ C(=O)R ３ｆ , -NR ３ｃ C (=O) OR ３ｂ , -NR ３ｃ C(=O)NR ３ｃ R ３ｄ , -S(=O)R ３ｇ , -S (=O) OR ３ｂ , -OS(=O)R ３ｇ , -OS(=O)OR ３ｂ , -S(=O)NR ３ｃ R ３ｄ , -NR ３ｃ S(=O)R ３ｇ , -NR ３ｃ S (= O) OR ３ｂ , -OS(=O)NR ３ｃ R ３ｄ , -NR ３ｃ S(=O)NR ３ｃ R ３ｄ , -S (=O) ２ R ３ｈ , -S (=O) ２ OR ３ｂ , -OS (=O) ２ R ３ｈ , -OS (=O) ２ OR ３ｂ , -S (=O) ２ NR ３ｃ R ３ｄ , -NR ３ｃ S (=O) ２ R ３ｈ , -NR ３ｃ S (=O) ２ OR ３ｂ , -OS (=O) ２ NR ３ｃ R ３ｄ , -NR ３ｃ S (=O) ２ NR ３ｃ R ３ｄ , -P (=O) (R ３ｉ ) ２ (These may be substituted with one or more substituents selected from a 3-14 member cycloalkyl group, a 3-14 member heterocyclic group, a 6-12 member aryl group, or a 5-14 member heteroaryl group.) R ４ is hydrogen, halogen, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy group, -CN, -OR ４２ , -NR ４３ R ４４ , -SR ４５ , -C(=O)R ４６ , -C (=O) OR ４２ -OC(=O)R ４６ , -C(=O)NR ４３ R ４４ , -NR ４３ C(=O)R ４６ , -S(=O)R ４７ , -S (=O) OR ４２ , -OS(=O)R ４７ , -S(=O)NR ４３ R ４４ , -NR ４３ S(=O)R ４７ , -S (=O) ２ R ４８ , -S (=O) ２ OR ４２ , -OS(=O)R ４８ , -S (=O) ２ NR ４３ R ４４ , -NR ４３ S (=O) ２ R ４８ , -P (=O) (R ４９ ) ２ , selected from 3-14 membered cycloalkyl groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups (however, the above-C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy groups, 3-14 membered cycloalkyl groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups are independently halogens and -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy group, -CN, oxo, -OR ４ｂ , -NR ４ｃ R ４ｄ , -SR ４ｅ , -C(=O)R ４ｆ , -C (=O) OR ４ｂ -OC(=O)R ４ｆ , -OC(=O)OR ４ｂ , -C(=O)NR ４ｃ R ４ｄ , -OC(=O)NR ４ｃ R ４ｄ , -C(=NR ４ｃ ) R ４ａ , -C(=NR ４ｃ ) NR ４ｃ R ４ｄ , -NR ４ｃ C (=NR ４ｃ ) NR ４ｃ R ４ｄ , -NR ４ｃ C(=O)R ４ｆ , -NR ４ｃ C (=O) OR ４ｂ , -NR ４ｃ C(=O)NR ４ｃ R ４ｄ , -S(=O)R ４ｇ , -S (=O) OR ４ｂ , -OS(=O)R ４ｇ , -OS(=O)OR ４ｂ , -S(=O)NR ４ｃ R ４ｄ , -NR ４ｃ S(=O)R ４ｇ , -NR ４ｃ S (= O) OR ４ｂ , -OS(=O)NR ４ｃ R ４ｄ , -NR ４ｃ S(=O)NR ４ｃ R ４ｄ , -S (=O) ２ R ４ｈ , -S (=O) ２ OR ４ｂ , -OS (=O) ２ R ４ｈ , -OS (=O) ２ OR ４ｂ , -S (=O) ２ NR ４ｃ R ４ｄ , -NR ４ｃ S (=O) ２ R ４ｈ , -NR ４ｃ S (=O) ２ OR ４ｂ , -OS (=O) ２ NR ４ｃ R ４ｄ , -NR ４ｃ S (=O) ２ NR ４ｃ R ４ｄ , -P (=O) (R ４ｉ ) ２ (These may be substituted with one or more substituents selected from a 3-14 member cycloalkyl group, a 3-14 member heterocyclic group, a 6-12 member aryl group, or a 5-14 member heteroaryl group.) R ５ is hydrogen, halogen, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy group, -CN, -OR ５２ , -NR ５３ R ５４ , -SR ５５ , -C(=O)R ５６ , -C (=O) OR ５２ -OC(=O)R ５６ , -C(=O)NR ５３ R ５４ , -NR ５３ C(=O)R ５６ , -S(=O)R ５７ , -S (=O) OR ５２ , -OS(=O)R ５７ , -S(=O)NR ５３ R ５４ , -NR ５３ S(=O)R ５７ , -S (=O) ２ R ５８ , -S (=O) ２ OR ５２ , -OS(=O)R ５８ , -S (=O) ２ NR ５３ R ５４ , -NR ５３ S (=O) ２ R ５８ , -P (=O) (R ５９ ) ２ , selected from 3-14 membered cycloalkyl groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups (however, the above-C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy groups, 3-14 membered cycloalkyl groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups are independently halogens and -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy group, -CN, oxo, -OR ５ｂ , -NR ５ｃ R ５ｄ、 -SR ５ｅ , -C(=O)R ５ｆ , -C (=O) OR ５ｂ -OC(=O)R ５ｆ , -OC(=O)OR ５ｂ , -C(=O)NR ５ｃ R ５ｄ , -OC(=O)NR ５ｃ R ５ｄ , -C(=NR ５ｃ ) R ５ａ , -C(=NR ５ｃ ) NR ５ｃ R ５ｄ , -NR ５ｃ C (=NR ５ｃ ) NR ５ｃ R ５ｄ , -NR ５ｃ C(=O)R ５ｆ , -NR ５ｃ C (=O) OR ５ｂ , -NR ５ｃ C(=O)NR ５ｃ R ５ｄ , -S(=O)R ５ｇ , -S (=O) OR ５ｂ , -OS(=O)R ５ｇ , -OS(=O)OR ５ｂ , -S(=O)NR ５ｃ R ５ｄ , -NR ５ｃ S(=O)R ５ｇ , -NR ５ｃ S (= O) OR ５ｂ , -OS(=O)NR ５ｃ R ５ｄ , -NR ５ｃ S(=O)NR ５ｃ R ５ｄ , -S (=O) ２ R ５ｈ , -S (=O) ２ OR ５ｂ , -OS (=O) ２ R ５ｈ , -OS (=O) ２ OR ５ｂ , -S (=O) ２ NR ５ｃ R ５ｄ , -NR ５ｃ S (=O) ２ R ５ｈ , -NR ５ｃ S (=O) ２ OR ５ｂ , -OS (=O) ２ NR ５ｃ R ５ｄ , -NR ５ｃ S (=O) ２ NR ５ｃ R ５ｄ , -P (=O) (R ５ｉ ) ２ (These may be substituted with one or more substituents selected from a 3-14 member cycloalkyl group, a 3-14 member heterocyclic group, a 6-12 member aryl group, or a 5-14 member heteroaryl group.) Preferably, R ４ and R ５ These two, together with the linked atoms, form a 3-14 membered carbon ring, a 3-14 membered hetero ring, a 6-12 membered aromatic ring, or a 5-14 membered hetero aromatic ring, and each of these rings independently forms n ３ Individual R Ｓ３ It may also be replaced with R Ｓ３ Each instance, halogen and -C are independently identified. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -CN, -NO ２ , -N ３ , oxo, -OR Ｓ３２ , -NR Ｓ３３ R Ｓ３４ , -SR Ｓ３５ , -C(=O)R Ｓ３６ , -C (=O) OR Ｓ３２ -OC(=O)R Ｓ３６ , -OC(=O)OR Ｓ３２ , -C(=O)NR Ｓ３３ R Ｓ３４ , -OC(=O)NR Ｓ３３ R Ｓ３４ , -C(=NR Ｓ３３ ) R Ｓ３１ , -C(=NR Ｓ３３ ) NR Ｓ３３ R Ｓ３４ , -NR Ｓ３３ C (=NR Ｓ３３ ) NR Ｓ３３ R Ｓ３４ , -NR Ｓ３３ C(=O)R Ｓ３６ , -NR Ｓ３３ C (=O) OR Ｓ３２ , -NR Ｓ３３ C(=O)NR Ｓ３３ R Ｓ３４ , -S(=O)R Ｓ３７ , -S (=O) OR Ｓ３２ , -OS(=O)R Ｓ３７ , -OS(=O)OR Ｓ３２ , -S(=O)NR Ｓ３３ R Ｓ３４ , -NR Ｓ３３ S(=O)R Ｓ３７ , -NR Ｓ３３ S (= O) OR Ｓ３２ , -OS(=O)NR Ｓ３３ R Ｓ３４ , -NR Ｓ３３ S(=O)NR Ｓ３３ R Ｓ３４ , -S (=O) ２ R Ｓ３８ , -S (=O) ２ OR Ｓ３２ , -OS (=O) ２ R Ｓ３８ , -OS (=O) ２ OR Ｓ３２ , -S (=O) ２ NR Ｓ３３ R Ｓ３４ , -NR Ｓ３３ S (=O) ２ R Ｓ３８ , -NR Ｓ３３ S (=O) ２ OR Ｓ３２ , -OS (=O) ２ NR Ｓ３３ R Ｓ３４ , -NR Ｓ３３ S (=O) ２ NR Ｓ３３ R Ｓ３４ , -P (=O) (R Ｓ３９ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups (however, the above-C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～１０ Alkoxy groups, 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups are independently halogens, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -CN, -NO ２ , -N ３ , oxo, -OR Ｓ３ｂ , -NR Ｓ３ｃ R Ｓ３ｄ , -SR Ｓ３ｅ , -C(=O)R Ｓ３ｆ 、-C(=O)OR Ｓ３ｂ 、-OC(=O)R Ｓ３ｆ 、-OC(=O)OR Ｓ３ｂ 、-C(=O)NR Ｓ３ｃ R Ｓ３ｄ 、-OC(=O)NR Ｓ３ｃ R Ｓ３ｄ 、-C(=NR Ｓ３ｃ )R Ｓ３ａ 、-C(=NR Ｓ３ｃ )NR Ｓ３ｃ R Ｓ３ｄ 、-NR Ｓ３ｃ C(=NR Ｓ３ｃ )NR Ｓ３ｃ R Ｓ３ｄ 、-NR Ｓ３ｃ C(=O)R Ｓ３ｆ 、-NR Ｓ３ｃ C(=O)OR Ｓ３ｂ 、-NR Ｓ３ｃ C(=O)NR Ｓ３ｃ R Ｓ３ｄ 、-S(=O)R Ｓ３ｇ 、-S(=O)OR Ｓ３ｂ 、-OS(=O)R Ｓ３ｇ 、-OS(=O)OR Ｓ３ｂ 、-S(=O)NR Ｓ３ｃ R Ｓ３ｄ 、-NR Ｓ３ｃ S(=O)R Ｓ３ｇ 、-NRS ３ａ S(=O)OR Ｓ３ｂ 、-OS(=O)NR Ｓ３ｃ R Ｓ３ｄ 、-NR Ｓ３ｃ S(=O)NR Ｓ３ｃ R Ｓ３ｄ 、-S(=O) ２ R Ｓ３ｈ 、-S(=O) ２ OR Ｓ３ｂ 、-OS(=O) ２ R Ｓ３ｈ 、-OS(=O) ２ OR Ｓ３ｂ 、-S(=O) ２ NR Ｓ３ｃ R Ｓ３ｄ 、-NR Ｓ３ｃ S(=O) ２ R Ｓ３ｈ 、-NR Ｓ３ｃ S(=O) ２ OR Ｓ３ｂ , -OS (=O) ２ NR Ｓ３ｃ R Ｓ３ｄ , -NR Ｓ３ｃ S (=O) ２ NR Ｓ３ｃ R Ｓ３ｄ , -P (=O) (R Ｓ３ｉ ) ２ (These may be substituted with one or more substituents selected from a 3-14 membered carbon ring, a 3-14 membered heterocyclic group, a 6-12 membered aryl group, or a 5-14 membered heteroaryl group.) n ３ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. n ４ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. Y １ は、-C(R Ｙ１１ ) ２ -、-R Ｙ１１ C=CR Ｙ１１ -、 【Chemistry 2】 -C(=O)-, -O-, -NR Ｙ１３ -, -S-, -S(=O)-, -S(=O) ２ -, -P(=O)R Ｙ１９ -, *-C(=O)O-, *-OC(=O)-, *-C(=O)NR Ｙ１３ -, *-NR Ｙ１３ C(=O)-, *-S(=O)O-, *-OS(=O)-, *-S(=O)NR Ｙ１３ -, *-NR Ｙ１３ S(=O)-, *-S(=O) ２ O-, *-OS(=O) ２ -, *-S(=O) ２ NR Ｙ１３ -, *-NR Ｙ１３ S(=O) ２ - or *-NR Ｙ１３ P(=O)R Ｙ１９ selected from * is the base 【Transformation 3】 It shows the connection point with, Ring A is selected from a 3-14 member carbon ring, a 3-14 member hetero ring, a 6-14 member aromatic ring, or a 5-14 member hetero aromatic ring, and each hetero ring independently contains 1, 2, 3, 4, 5, or 6 N, O, S, S(=O), S(=O) ２ It contains heteroatoms selected from, and each heteroaromatic ring independently contains 1, 2, 3, 4, 5, or 6 heteroatoms selected from N, O, or S, R Ｓ１ Each instance, halogen and -C are independently identified. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -CN, -NO ２ , -N ３ , oxo, -OR Ｓ１２ , -NR Ｓ１３ R Ｓ１４ , -SR Ｓ１５ , -C(=O)R Ｓ１６ , -C (=O) OR Ｓ１２ -OC(=O)R Ｓ１６ , -OC(=O)OR Ｓ１２ , -C(=O)NR Ｓ１３ R Ｓ１４ , -OC(=O)NR Ｓ１３ R Ｓ１４ , -C(=NR Ｓ１３ ) R Ｓ１１ , -C(=NR Ｓ１３ ) NR Ｓ１３ R Ｓ１４ , -NR Ｓ１３ C (=NR Ｓ１３ ) NR Ｓ１３ R Ｓ１４ , -NR Ｓ１３ C(=O)R Ｓ１６ , -NR Ｓ１３ C (=O) OR Ｓ１２ , -NR Ｓ１３ C(=O)NR Ｓ１３ R Ｓ１４ , -S(=O)R Ｓ１７ , -S (=O) OR Ｓ１２ , -OS(=O)R Ｓ１７ , -OS(=O)OR Ｓ１２ , -S(=O)NR Ｓ１３ R Ｓ１４ , -NR Ｓ１３ S(=O)R Ｓ１７ , -NR Ｓ１３ S (= O) OR Ｓ１２ , -OS(=O)NR Ｓ１３ R Ｓ１４ , -NR Ｓ１３ S(=O)NR Ｓ１３ R Ｓ１４ , -S (=O) ２ R Ｓ１８ , -S (=O) ２ OR Ｓ１２ , -OS (=O) ２ R Ｓ１８ , -OS (=O) ２ OR Ｓ１２ , -S (=O) ２ NR Ｓ１３ R Ｓ１４ , -NR Ｓ１３ S (=O) ２ R Ｓ１８ , -NR Ｓ１３ S (=O) ２ OR Ｓ１２ , -OS (=O) ２ NR Ｓ１３ R Ｓ１４ , -NR Ｓ１３ S (=O) ２ NR Ｓ１３ R Ｓ１４ , -P (=O) (R Ｓ１９ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups (however, the above-C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～１０ Alkoxy groups, 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups are independently halogens, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -CN, -NO ２ , -N ３ , oxo, -OR Ｓ１ｂ , -NR Ｓ１ｃ R Ｓ１ｄ , -SR Ｓ１ｅ , -C(=O)R Ｓ１ｆ 、-C(=O)OR Ｓ１ｂ 、-OC(=O)R Ｓ１ｆ 、-OC(=O)OR Ｓ１ｂ 、-C(=O)NR Ｓ１ｃ R Ｓ１ｄ 、-OC(=O)NR Ｓ１ｃ R Ｓ１ｄ 、-C(=NR Ｓ１ｃ )R Ｓ１ａ 、-C(=NR Ｓ１ｃ )NR Ｓ１ｃ R Ｓ１ｄ 、-NR Ｓ１ｃ C(=NR Ｓ１ｃ )NR Ｓ１ｃ R Ｓ１ｄ 、-NR Ｓ１ｃ C(=O)R Ｓ１ｆ 、-NR Ｓ１ｃ C(=O)OR Ｓ１ｂ 、-NR Ｓ１ｃ C(=O)NR Ｓ１ｃ R Ｓ１ｄ 、-S(=O)R Ｓ１ｇ 、-S(=O)OR Ｓ１ｂ 、-OS(=O)R Ｓ１ｇ 、-OS(=O)OR Ｓ１ｂ 、-S(=O)NR Ｓ１ｃ R Ｓ１ｄ 、-NR Ｓ１ｃ S(=O)R Ｓ１ｇ 、-NR Ｓ１ａ S(=O)OR Ｓ１ｂ 、-OS(=O)NR Ｓ１ｃ R Ｓ１ｄ 、-NR Ｓ１ｃ S(=O)NR Ｓ１ｃ R Ｓ１ｄ 、-S(=O) ２ R Ｓ１ｈ 、-S(=O) ２ OR Ｓ１ｂ 、-OS(=O) ２ R Ｓ１ｈ 、-OS(=O) ２ OR Ｓ１ｂ 、-S(=O) ２ NR Ｓ１ｃ R Ｓ１ｄ 、-NR Ｓ１ｃ S(=O) ２ R Ｓ１ｈ 、-NR Ｓ１ｃ S(=O) ２ OR Ｓ１ｂ , -OS (=O) ２ NR Ｓ１ｃ R Ｓ１ｄ , -NR Ｓ１ｃ S (=O) ２ NR Ｓ１ｃ R Ｓ１ｄ , -P (=O) (R Ｓ１ｉ ) ２ (These may be substituted with one or more substituents selected from a 3-14 membered carbon ring, a 3-14 membered heterocyclic group, a 6-12 membered aryl group, or a 5-14 membered heteroaryl group.) n １ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. Ring B is selected from a 3-14 member carbon ring, a 3-14 member hetero ring, a 6-14 member aromatic ring, or a 5-14 member hetero aromatic ring, and each hetero ring independently contains 1, 2, 3, or 4 N, O, S, S(=O), S(=O) ２ It contains heteroatoms selected from, and each heteroaromatic ring independently contains 1, 2, or 3 heteroatoms selected from N, O, or S. R Ｓ２ is, each time of appearance, independently a halogen, -C １～１０ alkyl group, -C ２～６ alkenyl group, -C ２～６ alkynyl group, -C １～１０ alkoxy group, halogenated C １～１０ alkyl group, halogenated C １～１０ alkoxy group, -CN, -NO ２ , -N ３ , oxo, -OR Ｓ２２ , -NR Ｓ２３ R Ｓ２４ , -SR Ｓ２５ , -C(=O)R Ｓ２６ , -C(=O)OR Ｓ２２ , -OC(=O)R Ｓ２６ , -OC(=O)OR Ｓ２２ , -C(=O)NR Ｓ２３ R Ｓ２４ , -OC(=O)NR Ｓ２３ R Ｓ２４ , -C(=NR Ｓ２３ )R Ｓ２１ , -C(=NR Ｓ２３ )NR Ｓ２３ R Ｓ２４ , -NR Ｓ２３ C(=NR Ｓ２３ )NR Ｓ２３ R Ｓ２４ , -NR Ｓ２３ C(=O)R Ｓ２６ , -NR Ｓ２３ C(=O)OR Ｓ２２ , -NR Ｓ２３ C(=O)NR Ｓ２３ R Ｓ２４ , -S(=O)R Ｓ２７ , -S(=O)OR Ｓ２２ , -OS(=O)R Ｓ２７ , -OS(=O)OR<​​​​​​​​​​​​​​​​​​​​​​, -S (=O) ２ R Ｓ２８ , -S (=O) ２ OR Ｓ２２ , -OS (=O) ２ R Ｓ２８ , -OS (=O) ２ OR Ｓ２２ , -S (=O) ２ NR Ｓ２３ R Ｓ２４ , -NR Ｓ２３ S (=O) ２ R Ｓ２８ , -NR Ｓ２３ S (=O) ２ OR Ｓ２２ , -OS (=O) ２ NR Ｓ２３ R Ｓ２４ , -NR Ｓ２３ S (=O) ２ NR Ｓ２３ R Ｓ２４ , -P (=O) (R Ｓ２９ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups (however, the above-C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～１０ Alkoxy groups, 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups are independently halogens, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -CN, -NO ２ , -N ３ , oxo, -OR Ｓ２ｂ , -NR Ｓ２ｃ R Ｓ２ｄ , -SR Ｓ２ｅ , -C(=O)R Ｓ２ｆ 、-C(=O)OR Ｓ２ｂ 、-OC(=O)R Ｓ２ｆ 、-OC(=O)OR Ｓ２ｂ 、-C(=O)NR Ｓ２ｃ R Ｓ２ｄ 、-OC(=O)NR Ｓ２ｃ R Ｓ２ｄ 、-C(=NR Ｓ２ｃ )R Ｓ２ａ 、-C(=NR Ｓ２ｃ )NR Ｓ２ｃ R Ｓ２ｄ 、-NR Ｓ２ｃ C(=NR Ｓ２ｃ )NR Ｓ２ｃ R Ｓ２ｄ -NR Ｓ２ｃ C(=O)R Ｓ２ｆ 、-NR Ｓ２ｃ C(=O)OR Ｓ２ｂ 、-NR Ｓ２ｃ C(=O)NR Ｓ２ｃ R Ｓ２ｄ 、-S(=O)R Ｓ２ｇ 、-S(=O)OR Ｓ２ｂ 、-OS(=O)R Ｓ２ｇ 、-OS(=O)OR Ｓ２ｂ 、-S(=O)NR Ｓ２ｃ R Ｓ２ｄ 、-NR Ｓ２ｃ S(=O)R Ｓ２ｇ 、-NR Ｓ２ａ S(=O)OR Ｓ２ｂ 、-OS(=O)NR Ｓ２ｃ R Ｓ２ｄ 、-NR Ｓ２ｃ S(=O)NR Ｓ２ｃ R Ｓ２ｄ 、-S(=O) ２ R Ｓ２ｈ 、-S(=O) ２ OR Ｓ２ｂ 、-OS(=O) ２ R Ｓ２ｈ 、-OS(=O) ２ OR Ｓ２ｂ 、-S(=O) ２ NR Ｓ２ｃ R Ｓ２ｄ 、-NR Ｓ２ｃ S(=O) ２ R Ｓ２ｈ 、-NR Ｓ２ｃ S(=O) ２ OR Ｓ２ｂ , -OS (=O) ２ NR Ｓ２ｃ R Ｓ２ｄ , -NR Ｓ２ｃ S (=O) ２ NR Ｓ２ｃ R Ｓ２ｄ , -P (=O) (R Ｓ２ｉ ) ２ (These may be substituted with one or more substituents selected from a 3-14 membered carbon ring, a 3-14 membered heterocyclic group, a 6-12 membered aryl group, or a 5-14 membered heteroaryl group.) n ２ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. R ３１ , R Ｓ１１ , R Ｓ２１ or R Ｙ１１ Each instance, it independently produces hydrogen, halogen, and -C. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -CN, -NO ２ , -N ３ , oxo, -OR ６ｂ , -NR ６ｃ R ６ｄ , -SR ６ｅ , -C(=O)R ６ｆ , -C (=O) OR ６ｂ -OC(=O)R ６ｆ , -OC(=O)OR ６ｂ , -C(=O)NR ６ｃ R ６ｄ , -OC(=O)NR ６ｃ R ６ｄ , -C(=NR ６ｃ ) R ６ａ , -C(=NR ６ｃ ) NR ６ｃ R ６ｄ , -NR ６ｃ C (=NR ６ｃ ) NR ６ｃ R ６ｄ , -NR ６ｃ C(=O)R ６ｆ , -NR ６ｃ C (=O) OR ６ｂ , -NR ６ｃ C(=O)NR ６ｃ R ６ｄ , -S(=O)R ６ｇ , -S (=O) OR ６ｂ , -OS(=O)R ６ｇ , -OS(=O)OR ６ｂ , -S(=O)NR ６ｃ R ６ｄ , -NR ６ｃ S(=O)R ６ｇ , -NR ６ｃ S (= O) OR ６ｂ , -OS(=O)NR ６ｃ R ６ｄ、 -NR ６ｃ S(=O)NR ６ｃ R ６ｄ , -S (=O) ２ R ６ｈ , -S (=O) ２ OR ６ｂ , -OS (=O) ２ R ６ｈ , -OS (=O) ２ OR ６ｂ , -S (=O) ２ NR ６ｃ R ６ｄ , -NR ６ｃ S (=O) ２ R ６ｈ , -NR ６ｃ S (=O) ２ OR ６ｂ , -OS (=O) ２ NR ６ｃ R ６ｄ , -NR ６ｃ S (=O) ２ NR ６ｃ R ６ｄ、 -P (=O) (R ６ｉ ) ２ , selected from a 3-14 membered carbon ring group, a 3-14 membered heterocyclic group, a 6-14 membered aryl group, or a 5-14 membered heteroaryl group, wherein the 3-14 membered carbon ring group, the 3-14 membered heterocyclic group, the 6-14 membered aryl group, or the 5-14 membered heteroaryl group contains one or more halogens or halogenated C １～６ It may be substituted with a substituent selected from alkyl groups. R １２ , R １５ , R ２２ , R ２５ , R ３２ , R ３５ , R ４２ , R ４５ , R ５２ , R ５５ , R Ｓ１２ , R Ｓ１５ , R Ｓ２２ , R Ｓ２５ , R Ｓ３２ or R Ｓ３５ Each time it appears, hydrogen, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -C(=O)R ７ｆ , -C (=O) OR ７ｂ , -S(=O)R ７ｇ , -S (=O) OR ７ｂ , -S (=O) ２ R ７ｈ , -S (=O) ２ OR ７ｂ , -P (=O) (R ７ｉ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups, R Ｙ１３ , R １３ , R １４ , R ２３ , R ２４ , R ３３ , R ３４ , R ４３ , R ４４ , R ５３ , R ５４ , R Ｓ１３ , R Ｓ１４ , R Ｓ２３ , R Ｓ２４ , R Ｓ３３ or R Ｓ３４ Each time it appears, hydrogen, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -C(=O)R ８ｆ , -C (=O) OR ８ｂ , -C(=O)NR ８ｃ R ８ｄ , -S(=O)R ８ｇ , -S (=O) OR ８ｂ , -S(=O)NR ８ｃ R ８ｄ , -S (=O) ２ R ８ｈ , -S (=O) ２ OR ８ｂ , -S (=O) ２ NR ８ｃ R ８ｄ、 -P (=O) (R ８ｉ ) ２ , selected from a 3-14 membered carbon ring group, a 3-14 membered heterocyclic group, a 6-14 membered aryl group, or a 5-14 membered heteroaryl group, the -C ２～６ The alkynyl group, 3-14 membered carbon ring group, 3-14 membered heterocyclic group, 6-14 membered aryl group, or 5-14 membered heteroaryl group is one or more -C １～６ Alkyl alkyl groups, Si(C １～６ (Alkyl group) ３ , halogenated C １～６ It may be substituted with a substituent selected from alkyl groups or halogens. R Ｙ１９ , R １６ , R １７ , R １８ , R １９ , R ２６ , R ２７ , R ２８ , R ２９ , R ３６ , R ３７ , R ３８ , R ３９ , R ４６ , R ４７ , R ４８ , R ４９ , R ５６ , R ５７ , R ５８ , R ５９ , R Ｓ１６ , R Ｓ１７ , R Ｓ１８ , R Ｓ１９ , R Ｓ２６ , R Ｓ２７ , R Ｓ２８ , R Ｓ２９ , R Ｓ３６ , R Ｓ３７ , R Ｓ３８ or R Ｓ３９ Each time it appears, it is hydrogen, halogen, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -OR ９ｂ , -NR ９ｃ R ９ｄ , selected from a 3-14 membered carbon ring group, a 3-14 membered heterocyclic group, a 6-14 membered aryl group, or a 5-14 membered heteroaryl group, wherein the 3-14 membered carbon ring group, the 3-14 membered heterocyclic group, the 6-14 membered aryl group, or the 5-14 membered heteroaryl group is one or more -C １～６ Alkyl alkyl groups, halogenated C １～６ Alkyl alkyl groups, -CN, halogens, or -C(=O)O-C １～６ It may be substituted with a substituent selected from alkyl groups. Preferably, (R １３ and R １４ ), (R ２３ and R ２４ ), (R ３３ and R ３４ ), (R ４３ and R ４４ ), (R ５３ and R ５４ ), (R Ｓ１３ and R Ｓ１４ ), (R Ｓ２３ and R Ｓ２４ ) or (Note Ｓ３３ and R Ｓ３４ These two components, together with the nitrogen atom linked to them, form a 3-14 member heterocyclic base ring or a 5-14 member heterocyclic aromatic ring, the 3-14 member heterocyclic ring containing 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O, S, SO or SO2, the 3-14 member heterocyclic aromatic ring containing 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O, S, and each of the rings independently contains n ６ Individual R Ｓ４ It may also be replaced with R Ｓ４ Each instance, halogen and -C are independently identified. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -CN, -NO ２ , -N ３ , oxo, -OR Ｓ４ｂ , -NR Ｓ４ｃ R Ｓ４ｄ , -SR Ｓ４ｅ , -C(=O)R Ｓ４ｇ , -C (=O) OR Ｓ４ｂ -OC(=O)R Ｓ４ｆ , -OC(=O)OR Ｓ４ｂ , -C(=O)NR Ｓ４ｃ R Ｓ４ｄ , -OC(=O)NR Ｓ４ｃ R Ｓ４ｄ , -C(=NR Ｓ４ｃ )RS4a, -C(=NR Ｓ４ｃ ) NR Ｓ４ｃ R Ｓ４ｄ , -NR Ｓ４ｃ C (=NR Ｓ４ｃ ) NR Ｓ４ｃ R Ｓ４ｄ , -NR Ｓ４ｃ C(=O)R Ｓ４ｆ , -NR Ｓ４ｃ C (=O) OR Ｓ４ｂ , -NR Ｓ４ｃ C(=O)NR Ｓ４ｃ R Ｓ４ｄ , -S(=O)R Ｓ４ｇ , -S (=O) OR Ｓ４ｂ , -OS(=O)R Ｓ４ｇ , -OS(=O)OR Ｓ４ｂ , -S(=O)NR Ｓ４ｃ R Ｓ４ｄ , -NR Ｓ４ｃ S(=O)R Ｓ４ｇ , -NR Ｓ４ｃ S (= O) OR Ｓ４ｂ , -OS(=O)NR Ｓ４ｃ R Ｓ４ｄ , -NR Ｓ４ｃ S(=O)NR Ｓ４ｃ R Ｓ４ｄ , -S (=O) ２ R Ｓ４ｈ , -S (=O) ２ OR Ｓ４ｂ , -OS (=O) ２ R Ｓ４ｈ , -OS (=O) ２ OR Ｓ４ｂ , -S (=O) ２ NR Ｓ４ｃ R Ｓ４ｄ , -NR Ｓ４ｃ S (=O) ２ R Ｓ４ｈ , -NR Ｓ４ｃ S (=O) ２ OR Ｓ４ｂ , -OS (=O) ２ NR Ｓ４ｃ R Ｓ４ｄ , -NR Ｓ４ｃ S (=O) ２ NR Ｓ４ｃ R Ｓ４ｄ , -P (=O) (R Ｓ４ｉ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups, n ６ is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. R １ａ , R ２ａ , R ３ａ , R ４ａ , R ５ａ , R ６ａ , R Ｓ１ａ , R Ｓ２ａ , R Ｓ３ａ or R Ｓ４ａ Each instance, it independently produces hydrogen, halogen, and -C. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -OR Ｚ１ｂ , -NR Ｚ１ｃ R Ｚ１ｄ , -SR Ｚ１ｅ , -C(=O)R Ｚ１ｆ , -C (=O) OR Ｚ１ｂ -OC(=O)R Ｚ１ｆ , -OC(=O)OR Ｚ１ｂ , -C(=O)NR Ｚ１ｃ R Ｚ１ｄ , -OC(=O)NR Ｚ１ｃ R Ｚ１ｄ , -C(=NR Ｚ１ｃ ) R Ｚ１ａ , -C(=NR Ｚ１ｃ ) NR Ｚ１ｃ R Ｚ１ｄ , -NR Ｚ１ｃ C (=NR Ｚ１ｃ ) NR Ｚ１ｃ R Ｚ１ｄ , -NR Ｚ１ｃ C(=O)R Ｚ１ｆ , -NR Ｚ１ｃ C (=O) OR Ｚ１ｂ , -NR Ｚ１ｃ C(=O)NR Ｚ１ｃ R Ｚ１ｄ , -S(=O)R Ｚ１ｇ , -S (=O) OR Ｚ１ｂ , -OS(=O)R Ｚ１ｇ , -OS(=O)OR Ｚ１ｂ , -S(=O)NR Ｚ１ｃ R Ｚ１ｄ , -NR Ｚ１ｃ S(=O)R Ｚ１ｇ , -NR Ｚ１ｃ S (= O) OR Ｚ１ｂ , -OS(=O)NR Ｚ１ｃ R Ｚ１ｄ , -NR Ｚ１ｃ S(=O)NR Ｚ１ｃ R Ｚ１ｄ , -S (=O) ２ R Ｚ１ｈ , -S (=O) ２ OR Ｚ１ｂ , -OS (=O) ２ R Ｚ１ｈ , -OS (=O) ２ OR Ｚ１ｂ , -S (=O) ２ NR Ｚ１ｃ R Ｚ１ｄ , -NR Ｚ１ｃ S (=O) ２ R Ｚ１ｈ , -NR Ｚ１ｃ S (=O) ２ OR Ｚ１ｂ , -OS (=O) ２ NR Ｚ１ｃ R Ｚ１ｄ -NR Ｚ１ｃ S (=O) ２ NR Ｚ１ｃ R Ｚ１ｄ , -P (=O) (R Ｚ１ｉ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups, R １ｂ , R １ｅ , R ２ｂ , R ２ｅ , R ３ｂ , R ３ｅ , R ４ｂ , R ４ｅ , R ５ｂ , R ５ｅ , R ６ｂ , R ６ｅ , R ７ｂ , R ８ｂ , R ９ｂ , R Ｓ１ｂ , R Ｓ１ｅ , R Ｓ２ｂ , R Ｓ２ｅ , R Ｓ３ｂ , R Ｓ３ｅ , R Ｓ４ｂ or R Ｓ４ｅ Each instance, hydrogen and -C appear independently. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -OR Ｚ２ｂ , -C(=O)R Ｚ２ｆ , -C (=O) OR Ｚ２ｂ , -S(=O)R Ｚ２ｇ , -S (=O) OR Ｚ２ｂ , -S (=O) ２ R Ｚ２ｈ , -S (=O) ２ OR Ｚ２ｂ , -P (=O) (R Ｚ２ｉ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups, R １ｃ , R １ｄ , R ２ｃ , R ２ｄ , R ３ｃ , R ３ｄ , R ４ｃ , R ４ｄ , R ５ｃ , R ５ｄ , R ６ｃ , R ６ｄ , R ８ｃ , R ８ｄ , R ９ｃ , R ９ｄ , R Ｓ１ｃ , R Ｓ１ｄ , R Ｓ２ｃ , R Ｓ２ｄ , R Ｓ３ｃ , R Ｓ３ｄ , R Ｓ４ｃ or R Ｓ４ｄ Each instance, hydrogen and -C appear independently. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -C(=O)R Ｚ３ｆ , -C(=O)NR Ｚ３ｃ R Ｚ３ｄ , -S(=O)R Ｚ３ｇ , -S(=O)NR Ｚ３ｃ R Ｚ３ｄ , -S (=O) ２ R Ｚ３ｈ , -S (=O) ２ NR Ｚ３ｃ R Ｚ３ｄ , -P (=O) (R Ｚ３ｉ ) ２ , selected from 3-14 membered carbon rings, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, and 5-14 membered heteroaryl groups, wherein the 3-14 membered carbon rings, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups consist of one or more C １～６ Alkyl alkyl groups, halogenated C １～６ Substituting with a substituent selected from alkyl groups or halogens, R １ｆ , R １ｇ , R １ｈ , R １ｉ , R ２ｆ , R ２ｇ , R ２ｈ , R ２ｉ , R ３ｆ , R ３ｇ , R ３ｈ , R ３ｉ , R ４ｆ , R ４ｇ , R ４ｈ , R ４ｉ , R ５ｆ , R ５ｇ , R ５ｈ , R ５ｉ , R ６ｆ , R ６ｇ , R ６ｈ , R ６ｉ , R ７ｆ , R ７ｇ , R ７ｈ , R ７ｉ , R ８ｆ , R ８ｇ , R ８ｈ , R ８ｉ , R Ｓ１ｆ , R Ｓ１ｇ , R Ｓ１ｈ , R Ｓ１ｉ , R Ｓ２ｆ , R Ｓ２ｇ , R Ｓ２ｈ , R Ｓ２ｉ , R Ｓ３ｆ , R Ｓ３ｇ , R Ｓ３ｈ , R Ｓ３ｉ , R Ｓ４ｆ , R Ｓ４ｇ , R Ｓ４ｈ or R Ｓ４ｉ Each instance, it independently produces hydrogen, halogen, and -C. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -OR Ｚ４ｂ , -NR Ｚ４ｃ R Ｚ４ｄ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, 5-14 membered heteroaryl groups, or 3-14 membered heterocyclic groups, one or more -C(=O)OR Ｚ４ｂ It may also be replaced with (R １ｃ and R １ｄ ), (R ２ｃ and R ２ｄ ), (R ３ｃ and R ３ｄ ), (R ４ｃ and R ４ｄ ), (R ５ｃ and R ５ｄ ), (R ６ｃ and R ６ｄ ), (R ８ｃ and R ８ｄ ), (R ９ｃ and R ９ｄ ), (R ｓ１ｃ and R ｓ１ｄ ), (R ｓ２ｃ and R ｓ２ｄ ), (R ｓ３ｃ and R ｓ３ｄ ) or (Note ｓ４ｃ and R ｓ４ｄ These two elements, together with the nitrogen atom linked to them, form a 3-14 membered heterocyclic base ring or a 5-14 membered heteroaromatic ring, and the 3-14 membered heteroaromatic ring consists of 1, 2, 3, 4, 5, or 6 N, O, S, SO or SO ２ The heteroatom is selected from, and the 3- to 14-membered heteroaromatic ring contains 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O, and S, and each of the rings independently contains n ７ Individual R Ｓ５ It may also be replaced with R Ｓ５ Each instance, halogen and -C are independently identified. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -CN, -NO ２ , -N ３ , oxo, -OR Ｚ５ｂ , -NR Ｚ５ｃ R Ｚ５ｄ , -SR Ｚ５ｅ , -C(=O)R Ｚ５ｆ , -C (=O) OR Ｚ５ｂ -OC(=O)R Ｚ５ｆ , -OC(=O)OR Ｚ５ｂ , -C(=O)NR Ｚ５ｃ R Ｚ５ｄ , -OC(=O)NR Ｚ５ｃ R Ｚ５ｄ , -C(=NR Ｚ５ｃ ) R Ｚ５ａ , -C(=NR Ｚ５ｃ ) NR Ｚ５ｃ R Ｚ５ｄ , -NR Ｚ５ｃ C (=NR Ｚ５ｃ ) NR Ｚ５ｃ R Ｚ５ｄ , -NR Ｚ５ｃ C(=O)R Ｚ５ｆ , -NR Ｚ５ｃ C (=O) OR Ｚ５ｂ , -NR Ｚ５ｃ C(=O)NR Ｚ５ｃ R Ｚ５ｄ , -S(=O)R Ｚ５ｇ , -S (=O) OR Ｚ５ｂ , -OS(=O)R Ｚ５ｇ , -OS(=O)OR Ｚ５ｂ , -S(=O)NR Ｚ５ｃ R Ｚ５ｄ , -NR Ｚ５ｃ S(=O)R Ｚ５ｇ , -NR Ｚ５ａ S (= O) OR Ｚ５ｂ , -OS(=O)NR Ｚ５ｃ R Ｚ５ｄ , -NR Ｚ５ｃ S(=O)NR Ｚ５ｃ R Ｚ５ｄ , -S (=O) ２ R Ｚ５ｈ , -S (=O) ２ OR Ｚ５ｂ , -OS (=O) ２ R Ｚ５ｈ , -OS (=O) ２ OR Ｚ５ｂ , -S (=O) ２ NR Ｚ５ｃ R Ｚ５ｄ , -NR Ｚ５ｃ S (=O) ２ R Ｚ５ｈ , -NR Ｚ５ｃ S (=O) ２ OR Ｚ５ｂ , -OS (=O) ２ NR Ｚ５ｃ R Ｚ５ｄ , -NR Ｚ５ｃ S (=O) ２ NR Ｚ５ｃ R Ｚ５ｄ , -P (=O) (R Ｚ５ｉ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-14 membered aryl groups, or 5-14 membered heteroaryl groups, n ７ is selected from 0, 1, 2, 3, 4, 5 or 6. R Ｚ１ａ or R Ｚ５ａ These are independently hydrogen, halogen, and -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -CN, -NO ２ , -N ３ , oxo, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -S (=O) (C １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -OC(=O)O(C １～６ Alkyl alkyl group), -NHC(=O)(OC １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)(=O)(OC) １～６ Alkyl alkyl group), -OC(=O)NH(C １～６ Alkyl alkyl group), -OC(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S(=O)(OC １～６ Alkyl alkyl group), -OS (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (OC １～６ Alkyl group), -OS (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S) (=O) ２ (C １～６ Alkyl group), -OS (=O) ２ O(C) １～６ Alkyl(alkyl group), -NHS(=O) ２ O(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ O(C) １～６ Alkyl group), -OS (=O) ２ NH ２ , -OS (=O) ２ NH(C) １～６ Alkyl group), -OS (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ NH ２ , -NHS (=O) ２ NH(C) １～６ Alkyl(alkyl group), -NHS(=O) ２ N(C) １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(S)(=O) ２ NH ２ , -N(C １～６ Alkyl(S)(=O) ２ NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ N(C) １～６ (Alkyl group) ２ , -PH(C １～６ Alkyl alkyl group), -P(C １～６ (Alkyl group) ２ , -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, R Ｚ１ｂ , R Ｚ１ｅ , R Ｚ２ｂ , R Ｚ４ｂ , R Ｚ５ｂ or R Ｚ５ｅ Hydrogen and -C are independent of each other. １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -C(=O)(C １～６ Alkyl alkyl group), -C (=O) (OC １～６ Alkyl alkyl group), -S (=O) (C １～６ Alkyl alkyl group), -S (=O) (OC １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ (OC １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, R Ｚ１ｃ , R Ｚ１ｄ , R Ｚ３ｃ , R Ｚ３ｄ , R Ｚ４ｃ , R Ｚ４ｄ , R Ｚ５ｃ or R Ｚ５ｄ These are independently hydrogen, halogen, and -C １～６ Alkyl alkyl group, -C ２～６ア Lukenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -C(=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, R Ｚ１ｆ , R Ｚ１ｇ , R Ｚ１ｈ , R Ｚ１ｉ , R Ｚ２ｆ , R Ｚ２ｇ , R Ｚ２ｈ , R Ｚ２ｉ , R Ｚ３ｆ , R Ｚ３ｇ , R Ｚ３ｈ , R Ｚ３ｉ , R Ｚ５ｆ , R Ｚ５ｇ , R Ｚ５ｈ or R Ｚ５ｉ These are independently hydrogen, halogen, and -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -OH, -O(C) １～６ Alkyl(alkyl group), -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ , selected from 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups (however, the above-C １～６ Alkyl alkyl groups, halogenated C １～６ Alkyl alkyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkoxy group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl groups, 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups are halogens, -C １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -C １～６ Alkoxy group, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NO ２ , -N ３ , oxo, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl alkyl group) C (=O) (C １～３ Alkyl alkyl group), -OC(=O)O(C １～３ Alkyl alkyl group), -NHC(=O)(OC １～３ Alkyl alkyl group), -N(C １～３ Alkyl(C)(=O)(OC) １～３ Alkyl alkyl group), -OC(=O)NH(C １～３ Alkyl alkyl group), -OC(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)NH ２ , -NHC(=O)NH(C １～３ Alkyl alkyl group), -NHC(=O)N(C １～３ (Alkyl group) ２ , -N(C １～３ Alkyl(C)(=O)NH ２ , -N(C １～３ Alkyl(C)(=O)NH(C) １～３ Alkyl alkyl group), -N(C １～３ Alkyl(C)C(=O)N(C) １～３ (Alkyl group) ２ , -S(=O)(OC １～３ Alkyl alkyl group), -OS (=O) (C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O)(C) １～３ Alkyl(alkyl group), -S (=O) ２ (OC １～３ Alkyl group), -OS (=O) ２ (C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O) ２ (C １～３ Alkyl group), -OS (=O) ２ O(C) １～３ Alkyl(alkyl group), -NHS(=O) ２ O(C) １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O) ２ O(C) １～３ Alkyl group), -OS (=O) ２ NH ２ , -OS (=O) ２ NH(C) １～３ Alkyl group), -OS (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ NH ２ , -NHS (=O) ２ NH(C) １～３ Alkyl(alkyl group), -NHS(=O) ２ N(C) １～３ (Alkyl group) ２ , -N(C １～３ Alkyl(S)(=O) ２ NH ２ , -N(C １～３ Alkyl(S)(=O) ２ NH(C) １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O) ２ N(C) １～３ (Alkyl group) ２ , -PH(C １～３ Alkyl alkyl group), -P(C １～３ (Alkyl group) ２ , -P(=O)H(C １～３ Alkyl alkyl group), -P (=O)(C １～３ (Alkyl group) ２ (The group may be substituted with one or more substituents selected from a 3-7 member cycloalkyl group, a 3-7 member cycloalkenyl group, a 3-7 member cycloalkynyl group, a 3-7 member heterocyclic group, a 6 member aryl group, a 10 member aryl group, or a 5-6 member heteroaryl group.) Each heterocyclic group, in each instance, independently contains 1, 2, 3, 4, 5, or 6 N, O, S, S(=O) or S(=O) molecules. ２ It contains heteroatoms selected from, Each heteroaryl group, upon its occurrence, independently contains one, two, three, four, five, or six heteroatoms selected from N, O, or S.

2. Y １ is -O-, -NR Ｙ１３ -, -S-, *-NR Ｙ１３ -C(=O)-, *-NR Ｙ１３ S (=O) - or * - NR Ｙ１３ S (=O) ２ - Selected from, * is the base 【Chemistry 4】 It shows the connection point with, R Ｙ１３ This is the same as the definition in claim 1. A compound represented by formula (I) as described in claim 1, its stereoisomer, its tautomer, its atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer or a pharmaceutically acceptable salt of its atropisomer.

3. Y １ is, -NR Ｙ１３ - or * - NR Ｙ１３ Selected from -C (=O)- * is the base 【Transformation 5】 It shows the connection point with, R Ｙ１３ This is the same as the definition in claim 1. A compound represented by formula (I) according to any one of claims 1 to 2, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

4. Y １ is, -NR Ｙ１３ - Selected from, R Ｙ１３ This is the same as the definition in claim 1. A compound represented by formula (I) according to any one of claims 1 to 3, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

5. Y １ *-NR Ｙ１３ Selected from -C (=O)- * is the base 【Transformation 6】 It shows the connection point with, R Ｙ１３ This is the same as the definition in claim 1. A compound represented by formula (I) according to any one of claims 1 to 3, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

6. R Ｙ１３ is hydrogen, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～６ Alkyl alkyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkoxy group, -C(=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from a 3-10 membered carbon ring group, a 3-10 membered heterocyclic group, a phenyl group, a naphthyl group, or a 5-10 membered heteroaryl group, Preferably, R Ｙ１３ These are hydrogen and -C, respectively, independently. １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy group, -C(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ Or selected from 3- to 7-membered cycloalkyl groups, More specifically, R Ｙ１３ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Transformation 7】 -CH ２ F、-CHF ２ 、-CF ３ 、-CH ２ CH ２ F、-CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ 、-CF ２ CH ３ 、-C(=O)(CH ３ )、-C(=O)(CH ２ CH ３ )、-C(=O)(CH(CH ３ ) ２ )、-S(=O)CH ３ 、-S(=O)(CH ２ CH ３ )、-S(=O)(CH(CH ３ ) ２ )、-S(=O) ２ CH ３ 、-S(=O) ２ (CH ２ CH ３ )、-S(=O) ２ (CH(CH ３ ) ２ )、 【Transformation 8】 Selected from, More specifically, R Ｙ１３ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, More preferably, R Ｙ１３ Each is independently selected from -H, A compound represented by formula (I) according to any one of claims 1 to 5, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

7. R Ｙ１３ Each is independently selected from -H, A compound represented by formula (I) according to any one of claims 1 to 6, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

8. Y １ is, -NR Ｙ１３ - Selected from, R Ｙ１３ These are independently -H and -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy group, -C(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ Or selected from 3- to 7-membered cycloalkyl groups, preferably R Ｙ１３ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 9】 -CH ２ F、-CHF ２ 、-CF ３ 、-CH ２ CH ２ F、-CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ 、-CF ２ CH ３ 、-C(=O)(CH ３ )、-C(=O)(CH ２ CH ３ )、-C(=O)(CH(CH ３ ) ２ )、-S(=O)CH ３ 、-S(=O)(CH ２ CH ３ )、-S(=O)(CH(CH ３ ) ２ )、-S(=O) ２ CH ３ 、-S(=O) ２ (CH ２ CH ３ )、-S(=O) ２ (CH(CH ３ ) ２ )、 【Chemistry 10】 Selected from, more preferably, R Ｙ１３ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, and more preferably R Ｙ１３ Each is independently selected from -H, A compound represented by formula (I) according to any one of claims 1 to 7, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

9. Y １ is -NH-, -N(CH ３ ) - or -N(CH ２ CH ３ ) - Selected from, A compound represented by formula (I) as described in claim 8, its stereoisomer, its tautomer, its atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer or a pharmaceutically acceptable salt of its atropisomer.

10. Y １ Selected from -NH- A compound represented by formula (I) according to any one of claims 8 to 9, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

11. Y １ *-NR Ｙ１３ Selected from -C (=O)- * is the base 【Chemistry 11】 It shows the connection point with, R Ｙ１３ These are independently -H and -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Selected from an alkoxy group or a 3- to 7-membered cycloalkyl group, preferably R Ｙ１３ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 12】 -CH ２ F、-CHF ２ 、-CF ３ 、-CH ２ CH ２ F、-CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ 、-CF ２ CH ３ 、 【Chemistry 13】 Selected from, more preferably, R Ｙ１３ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, and more preferably R Ｙ１３ Each is independently selected from -H, A compound represented by formula (I) according to any one of claims 1 to 7, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

12. Y １ are *-NH-C(=O)-, *-N(CH ３ )-C(=O)- or *-N(CH ２ CH ３ ) - C (= O) - selected, * is the base 【Chemistry 14】 This indicates the connection point with A compound represented by formula (I) according to claim 11, its stereoisomer, its tautomer, its atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer or a pharmaceutically acceptable salt of its atropisomer.

13. Y １ It is selected from *-NH-C(=O)- * is the base 【Chemistry 15】 This indicates the connection point with A compound represented by formula (I) according to any one of claims 11 to 12, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

14. n ４ n is selected from 0, 1, 2, 3, 4, 5 or 6, preferably n ４ n is selected from 0, 1, 2 or 3, and more preferably n ４ is selected from 0, 1 or 2, and more preferably n ４ It is selected from 0 or 1. A compound represented by formula (I) according to any one of claims 1 to 13, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

15. n ４ It is 0. A compound represented by formula (I) according to any one of claims 1 to 14, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

16. n ４ It is 1. A compound represented by formula (I) according to any one of claims 1 to 14, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

17. X １ N is A compound represented by formula (I) according to any one of claims 1 to 16, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

18. X １ CR ３ And, R ３ This is the same as the definition in claim 1. A compound represented by formula (I) according to any one of claims 1 to 16, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

19. R ４ or R ５ Each instance of these elements independently represents hydrogen, -F, -Cl, -Br, and -C. １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, Preferably, R ４ or R ５ Each instance independently represents hydrogen, -F, -Cl, -Br, and -CH. ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 16】 -CH ２ F, -CHF ２ -CF ３ 、-CH ２ CH ２ F, -CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ -CF ２ CH ３ 、-CN、-NH ２ 、-NH(CH) ３ )、-N(CH ３ ) ２ 、-NH(CH) ２ CH ３ )、-OH、-O-CH ３ 、-O-CH ２ CH ３ 、-SH、-S-CH ３ 、-S-CH ２ CH ３ 、-S(=O)CH ３ 、-S(=O)(CH ２ CH ３ )、-S(=O) ２ CH ３ 、-SS(=O) ２ (CH) ２ CH ３ )、-COOH、-C(=O)(CH ３ )、-C(=O)(CH ２ CH ３ )、-C(=O)(OCH ３ )、-C(=O)(OCH ２ CH ３ )、-OC(=O)(CH ３ )、-OC(=O)(CH ２ CH ３ )、-C(=O)NH ２ 、-C(=O)NH(CH ３ )、-C(=O)NH(CH ２ CH ３ )、-C(=O)N(CH ３ ) ２ 、-NHC(=O)(CH ３ )、-NHC(=O)(CH ２ CH ３ )、-S(=O)NH ２ 、-S(=O)NH(CH ３ )、-S(=O)NH(CH ２ CH ３ )、-S(=O)N(CH ３ ) ２ 、-NHS(=O)(CH ３ )、-NHS(=O)(CH ２ CH ３ )、-S(=O) ２ (OCH ３ )、-S(=O) ２ (OCH ２ CH ３ )、-S(=O) ２ NH ２ 、-SS(=O) ２ NH(CH) ３ )、-S(=O) ２ NH(CH) ２ CH ３ )、-S(=O) ２ N(CH) ３ ) ２ 、-NHSS(=O ２ (CH) ３ )、-NHS(=O) ２ (CH) ２ CH ３ ) 【Chemistry 17】 Selected from, More specifically, R ４ or R ５ Each instance of these is independently represented by -H, -F, -Cl, and -CH. ３ ien-CH ２ CH ３ , -CN, -COOH, -OH, -O-CH ３ , -O-CH ２ CH ３ , -SH, -S-CH ３ , -CF ３ ,-CHF ２ , -NH ２ ,-NH(CH ３ ), -N(CH ３ ) ２ , [Chemistry 18] -C(=0)NH ２ 、 【Chemistry 19】 Selected from, More preferably, R ４ or R ５ Each instance of these is independently -H and -CH. ３ or -CH ２ CH ３ Selected from, A compound represented by formula (I) according to any one of claims 1 to 18, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

20. R ４ is -H, -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, R ５ is -H, -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, A compound represented by formula (I) according to any one of claims 1 to 19, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

21. R ４ is selected from -H, A compound represented by formula (I) according to any one of claims 1 to 20, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

22. R ５ is selected from -H, A compound represented by formula (I) according to any one of claims 1 to 21, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

23. Y １ is, -NR Ｙ１３ - or * - NR Ｙ１３ -C (=O)- is selected, and * is the base 【Chemistry 20】 It shows the connection point with, R Ｙ１３ is hydrogen, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～６ Alkyl alkyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkoxy group, -C(=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from a 3-10 membered carbon ring group, a 3-10 membered heterocyclic group, a phenyl group, a naphthyl group, or a 5-10 membered heteroaryl group, preferably R Ｙ１３ These are hydrogen and -C, respectively, independently. １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy group, -C(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ Or selected from 3- to 7-membered cycloalkyl groups, more preferably R Ｙ１３ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ） ２ 、 【Chemistry 21】 -CH ２ F、-CHF ２ 、-CF ３ 、-CH ２ CH ２ F、-CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ 、-CF ２ CH ３ 、-C(=O)(CH ３ )、-C(=O)(CH ２ CH ３ )、-C(=O)(CH(CH ３ ) ２ )、-S(=O)CH ３ 、-S(=O)(CH ２ CH ３ )、-S(=O)(CH(CH ３ ) ２ )、-S(=O) ２ CH ３ 、-S(=O) ２ (CH ２ CH ３ )、-S(=O) ２ (CH(CH ３ ) ２ )、 【Chemistry 22】 Selected from, more preferably, R Ｙ１３ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, and more preferably R Ｙ１３ Each is independently selected from -H, n ４ n is selected from 0, 1, 2 or 3, preferably n ４ n is selected from 0, 1, or 2, and more preferably n ４ This is selected from 0 or 1. X １ is N or CR ３ And R ３ This is the same as the definition in claim 1, R ４ or R ５ Each instance of these elements independently represents hydrogen, -F, -Cl, -Br, and -C. １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, preferably R ４ or R ５ Each instance independently represents hydrogen, -F, -Cl, -Br, and -CH. ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 23】 -CH ２ F, -CHF ２ -CF ３ 、-CH ２ CH ２ F, -CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ -CF ２ CH ３ 、-CN、-NH ２ 、-NH(CH) ３ )、-N(CH ３ ) ２ 、-NH(CH) ２ CH ３ )、-OH、-O-CH ３ 、-O-CH ２ CH ３ 、-SH、-S-CH ３ 、-S-CH ２ CH ３ 、-S(=O)CH ３ 、-S(=O)(CH ２ CH ３ )、-S(=O) ２ CH ３ 、-SS(=O) ２ (CH) ２ CH ３ )、-COOH、-C(=O)(CH ３ )、-C(=O)(CH ２ CH ３ )、-C(=O)(OCH ３ )、-C(=O)(OCH ２ CH ３ )、-OC(=O)(CH ３ )、-OC(=O)(CH ２ CH ３ )、-C(=O)NH ２ 、-C(=O)NH(CH ３ )、-C(=O)NH(CH ２ CH ３ )、-C(=O)N(CH ３ ) ２ 、-NHC(=O)(CH ３ )、-NHC(=O)(CH ２ CH ３ )、-S(=O)NH ２ 、-S(=O)NH(CH ３ )、-S(=O)NH(CH ２ CH ３ )、-S(=O)N(CH ３ ) ２ 、-NHS(=O)(CH ３ )、-NHS(=O)(CH ２ CH ３ )、-S(=O) ２ (OCH ３ )、-S(=O) ２ (OCH ２ CH ３ )、-S(=O) ２ NH ２ 、-SS(=O) ２ NH(CH) ３ )、-S(=O) ２ NH(CH) ２ CH ３ )、-S(=O) ２ N(CH) ３ ) ２ 、-NHSS(=O) ２ (CH) ３ )、-NHS(=O) ２ (CH) ２ CH ３ ) 【Chemistry 24】 Selected from, more preferably, R ４ or R ５ Each instance of these is independently represented by -H, -F, -Cl, and -CH. ３ ien-CH ２ CH ３ , -CN, -COOH, -OH, -O-CH ３ , -O-CH ２ CH ３ , -SH, -S-CH ３ , -CF ３ ,-CHF ２ , -NH ２ ,-NH(CH ３ ), -N(CH ３ ) ２ , 【Chemistry 25】 -C(=0)NH ２ 、 【Chemistry 26】 Selected from, more preferably, R ４ or R ５ Each instance of these is independently -H and -CH. ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, and more preferably R ４ is selected from -H and R ４ is selected from -H, A compound represented by formula (I) according to any one of claims 1 to 22, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

24. base 【Chemistry 27】 teeth, 【Chemistry 28】 Selected from, R １ , R ２ and R ３ This is the same as the definition in claim 1. A compound represented by formula (I) according to any one of claims 1 to 23, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

25. base 【Chemistry 29】 teeth, 【Transformation 30】 Selected from, R １ , R ２ and R ３ This is the same as the definition in claim 1. A compound represented by formula (I) according to any one of claims 1 to 24, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

26. base 【Chemistry 31】 teeth, 【Chemistry 32】 Selected from, R １ , R ２ and R ３ This is the same as the definition in claim 1. A compound represented by formula (I) according to any one of claims 1 to 25, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

27. The aforementioned compound is selected from formula (I-1), formula (I-2), or formula (I-3), 【Transformation 33】 Ring A, R Ｓ１ , n １ , ring B, R Ｓ２ , n ２ , R １ , R ２ and R ３ This is the same as the definition in claim 1. A compound represented by formula (I) according to any one of claims 1 to 26, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

28. R ３ These are hydrogen, halogen, and -C, respectively, independently. １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl(alkyl group), -SH, -S(C １～６ (Alkyl alkyl group), - (C １～６ (Alkylene group)-C(=O)R ６ , -C(=O)R ６ -OC(=O)R ６ , -NHC(=O)R ６ , -N(C １～６ (Alkyl alkyl group) C(=O)R ６ , -S(=O)R ６ , -OS(=O)R ６ , -NHS(=O)R ６ , -N(C １～６ Alkyl(S)(=O)R ６ , -S (=O) ２ R ６ , -OS (=O) ２ R ６ , -NHS (=O) ２ R ６ , -N(C １～６ Alkyl(S)(=O) ２ R ６ , -P (=O) (R ６ )H, -P(=O)(R ６ ) ２ , -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , selected from a 3-14 membered carbon ring group, a 3-14 membered heterocyclic group, a 6-12 membered aryl group, or a 5-14 membered heteroaryl group, the -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～６ Alkyl alkyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkoxy groups, 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups are halogens, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl alkyl group), -S (=O) (OC １～６ Alkyl alkyl group), -OS (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ (OC １～６ Alkyl group), -OS (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ (C １～６ Alkyl(alkyl group), -PH(C １～６ Alkyl alkyl group), -P(C １～６ (Alkyl group) ２ , -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ They may be substituted with one or more substituents selected from 3- to 7-membered groups, 3- to 7-membered heterocyclic groups, 6- to 10-membered aryl groups, or 5- to 10-membered heteroaryl groups. R ６ is hydrogen, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -OH, -O(C) １～６ Alkyl(alkyl group), -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ , selected from a 3-14 membered carbon ring group, a 3-14 membered heterocyclic group, a 6-12 membered aryl group, or a 5-14 membered heteroaryl group, the R ６ is one or more R ６Ａ It may be replaced by the above R ６Ａ Each instance, halogen and -C are independently identified. １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl alkyl group), -S (=O) (OC １～６ Alkyl alkyl group), -OS (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ (OC １～６ Alkyl group), -OS (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ (C １～６ Alkyl(alkyl group), -PH(C １～６ Alkyl alkyl group), -P(C １～６ (Alkyl group) ２ , -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from 3-7 membered carbon ring groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, R ６Ａ The aforementioned (-C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy groups, 3-7 membered carbon ring groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups are halogens, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～６ Alkyl alkyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl alkyl group), -S (=O) (OC １～６ Alkyl alkyl group), -OS (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ (OC １～６ Alkyl group), -OS (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ (C １～６ Alkyl(alkyl group), -PH(C １～６ Alkyl alkyl group), -P(C １～６ (Alkyl group) ２ , -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , -Si(C １～６ (Alkyl group) ３ It may be substituted with one or more substituents selected from a 3- to 7-membered carbon ring group, a 3- to 7-membered heterocyclic group, a 6- to 10-membered aryl group, or a 5- to 10-membered heteroaryl group. Each heterocyclic group, in each instance, independently contains 1, 2, 3, 4, 5, or 6 N, O, S, S(=O) or S(=O) molecules. ２ It contains heteroatoms selected from, Each heteroaryl group, upon its appearance, independently contains one, two, three, four, five, or six heteroatoms selected from N, O, or S. A compound represented by formula (I) according to any one of claims 1 to 27, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

29. R ３ These are, independently, hydrogen, -F, -Cl, -Br, and -C. １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ (Alkyl alkyl group), - (C １～３ (Alkylene group)-C(=O)R ６ , -C(=O)R ６ -OC(=O)R ６ , -NHC(=O)R ６ , -N(C １～３ (Alkyl alkyl group) C(=O)R ６ , -S(=O)R ６ , -NHS(=O)R ６ , -N(C １～３ Alkyl(S)(=O)R ６ , -S (=O) ２ R ６ , -NHS (=O) ２ R ６ , -N(C １～３ Alkyl(S)(=O) ２ R ６ , selected from a 3-7 membered carbon ring group, a 3-7 membered heterocyclic group, a phenyl group, a naphthyl group, or a 5-10 membered heteroaryl group, the -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy groups, 3-7 membered carbon ring groups, 3-7 membered heterocyclic groups, phenyl groups, naphthyl groups, or 5-10 membered heteroaryl groups are halogens, -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkyl, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -C (=O) (OC １～３ Alkyl alkyl group) or -C (=O) (halogenated C １～３ It may be substituted with one or more substituents selected from alkyl groups. R ６ is hydrogen, -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -OH, -O(C) １～３ Alkyl(Hydrogen), -NH2, -NH(C １～４ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ , a 3-7 membered carbon ring group, a 3-7 membered heterocyclic group, a phenyl group, a naphthyl group, or a 5-10 membered heteroaryl group, and the R ６ is one or more R ６Ａ It may be replaced by the above R ６Ａ Each instance, halogen and -C are independently identified. １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～４ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered carbon ring groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, R ６Ａ The aforementioned (-C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy groups, 3-7 membered carbon ring groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups are halogens, -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkyl, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -C (=O) (halogenated C １～３ Alkyl alkyl group), -Si (C １～３ (Alkyl group) ３ They may be substituted with one or more substituents selected from the following: Each heterocyclic group, in each instance, independently contains 1, 2, 3, 4, 5, or 6 N, O, S, S(=O) or S(=O) molecules. ２ It contains heteroatoms selected from, Each heteroaryl group, upon its appearance, independently contains one, two, three, four, five, or six heteroatoms selected from N, O, or S. A compound represented by formula (I) according to any one of claims 1 to 28, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

30. R ３ These are independently -H, -F, -Cl, -Br, and -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ , - (C １～３ (Alkylene group)-C(=O)R ６ , -C(=O)R ６ , -NHC(=O)R ６ , -S (=O) ２ R ６ or -NHS (=O) ２ R ６ Selected from, the above-C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group or -C ２～３ The alkynyl group is a halogen, -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkyl, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -C (=O) (OC １～３ Alkyl alkyl group) or -C (=O) (halogenated C １～３ It may be substituted with 0, 1, 2, or 3 substituents selected from alkyl groups. R ６ is hydrogen, -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -OH, -O(C) １～３ Alkyl(alkyl group), -NH ２ ,-NH(C １～４ Alkyl alkyl group), -N(C １～４ (Alkyl group) ２ , a 3-7 membered carbon ring group, a 3-7 membered heterocyclic group, a phenyl group or a 5-10 membered heteroaryl group, and the R ６ This is 0, 1, 2, or 3 R ６Ａ It may be replaced by the above Ｒ６Ａ Each instance, halogen and -C are independently identified. １～４ Alkyl alkyl group, -C ２～３ Alkynyl group, -CN, -C(=O)(OC) １～４ Selected from alkyl groups, 3- to 7-membered heterocyclic groups, phenyl groups, or 5- to 10-membered heteroaryl groups, R ６Ａ The aforementioned (-C １～４ Alkyl alkyl group, -C ２～６ Alkynyl group, 3-7 membered heterocyclic group, phenyl group or 5-10 membered heteroaryl group) is -Si (C １～３ (Alkyl group) ３ , -C １～３ Alkyl or halogenated C １～３ It may be substituted with 0, 1, 2, or 3 substituents selected from alkyl groups. The aforementioned 3- to 7-membered carbon ring group is 【Transformation 34】 Selected from, The aforementioned 3- to 7-membered heterocyclic group is selected from morpholinyl group, azetidinyl group, tetrahydrofuranyl group, thiomorpholinyl group, tetrahydropyranyl group, tetrahydroimidazolyl group, piperidinyl group, pyrrolidinyl group, or piperazinyl group. The aforementioned 5-10 membered heteroaryl group is a furyl group, thienyl group, pyridyl group, pyrimidyl group, pyridazyl group, pyrazinyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, thiazolyl group, isothiazolyl group, oxazolyl group, isoxazolyl group, oxadiazolyl group, quinolyl group, isoquinolyl group, quinazolinyl group, quinoxalyl group, benzofuranyl group, benzooxazolyl group, benzoisoxazolyl group, benzothiazolyl group, Selected from benzimidazolyl group, indolyl group, indazolyl group, 1H-pyrrolo[2,3-b]pyradinyl group, 1H-imidazo[4,5-b]pyradyl group, 1H-imidazo[4,5-b]pyradinyl group, 1H-pyrazolo[4,3-c]pyradyl group, 2H-pyrazolo[3,4-b]thienyl group, pyrazolo[5,1-c][1,2,4]triazinyl group, thiazolo[4,5-b]pyradyl group, or pyrido[2,3-b]pyradyl group, A compound represented by formula (I) according to any one of claims 1 to 29, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

31. R ３ These are independently -H, -F, -Cl, -Br, and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 35】 -NH ２ ,-NH(CH ３ ), -NH(CH ２ CH ３ ), -N(CH ３ ) ２ , -C(=O)R ６ ien-CH ２ -C(=O)R ６ ien-CH ２ CH ２ -C(=O)R ６ , -CH(CH ３ )-C(=O)R ６ ien-CH ２ CH ２ CH ２ -C(=O)R ６ , -NHC(=O)R ６ , -S (=O) ２ R ６ or -NHS (=O) ２ R ６ Selected from the above 【Transformation 36】 is -C(=O)(OCH ３ ), -C(=O)(OCH ２ CH ３ ), -C(=O)(OCH ２ CH ２ CH ３ ) or -C (=O) (OCH (CH ３ ) ２ ) is replaced by, R ６ is hydrogen, -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 37】 -OH, -O-CH ３ , -O-CH ２ CH ３ , -O-CH(CH ３ ) ２ , -NH ２ ,-NH(CH ３ ), -NH(CH ２ CH ３ ), -NH(CH(CH ３ ) ２ ), -NH(C(CH ３ ) ３ ), -N(CH ３ ) ２ , a 3-7 membered carbon ring group, a 3-7 membered heterocyclic group, a phenyl group, or a 5-10 membered heteroaryl group, R ６ The aforementioned (-NH ２ , 【Transformation 38】 A phenyl group, a 3-7 membered heterocyclic group, or a 5-10 membered heteroaryl group may have 0, 1, 2, or 3 R ６Ａ It may be replaced by the above R ６Ａ Each instance of -F, -Cl, -Br, 【Chemistry 39】 -NH ２ 、-CH ３ 、-CH ２ CH ３ 、-CH ２ CH ２ CH ３ 、-CH(CH ３ ) ２ 、 【Chemistry 40】 -CN, -C(=O)(OCH ３ ), -C(=O)(OCH ２ CH ３ ), -C(=O)(OCH(CH ３ ) ２ ), -C(=O)(OC(CH ３ ) ３ ), selected from 5-10 membered heteroaryl groups, R ６Ａ The above ( 【Chemistry 41】 -NH ２ (or 5-10 member heteroaryl groups) are -F, -Cl, -Br, -CN, -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ ien-CH ２ F, -CHF ２ , -CF ３ ien-CH ２ CH ２ F, -CH ２ CHF ２ ien-CH ２ CF ３ yan-CHFCH ３ , -CF ２ CH ３ , -Si(CH(CH ３ ) ２ ) ３ It may be substituted with 0, 1, 2, or 3 substituents selected from the following: The aforementioned 3- to 7-membered carbon ring group is 【Chemistry 42】 Selected from, The aforementioned 3- to 7-membered heterocyclic groups are 【Chemistry 43】 Selected from, The aforementioned 5- to 10-membered heteroaryl group 【Chemistry 44】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 30, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

32. R ３ は、-Br、-NH ２ 、 【Chemistry 45】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 31, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

33. R １ These are, independently, hydrogen, -F, -Cl, -Br, and -C. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, phenyl groups, naphthyl groups, or 5-10 membered heteroaryl groups, Preferably, R １ These are, independently, hydrogen, -F, -Cl, -Br, and -CH, respectively. ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 46】 -CH ２ F, -CHF ２ -CF ３ 、-CH ２ CH ２ F, -CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ -CF ２ CH ３ 、-CN、-NH ２ 、-NH(CH) ３ )、-N(CH ３ ) ２ 、-NH(CH) ２ CH ３ )、-OH、-O-CH ３ 、-O-CH ２ CH ３ 、-SH、-S-CH ３ 、-S-CH ２ CH ３ 、-S(=O)CH ３ 、-S(=O)(CH ２ CH ３ )、-S(=O) ２ CH ３ 、-SS(=O) ２ (CH2CH) ３ )、-COOH、-C(=O)(CH ３ )、-C(=O)(CH ２ CH ３ )、-C(=O)(OCH ３ )、-C(=O)(OCH ２ CH ３ )、-OC(=O)(CH ３ )、-OC(=O)(CH ２ CH ３ )、-C(=O)NH ２ 、-C(=O)NH(CH ３ )、-C(=O)NH(CH ２ CH ３ )、-C(=O)N(CH ３ ) ２ 、-NHC(=O)(CH ３ )、-NHC(=O)(CH ２ CH ３ )、-S(=O)NH ２ 、-S(=O)NH(CH ３ )、-S(=O)NH(CH ２ CH ３ )、-S(=O)N(CH ３ ) ２ 、-NHS(=O)(CH ３ )、-NHS(=O)(CH ２ CH ３ )、-S(=O) ２ (OCH ３ )、-S(=O) ２ (OCH ２ CH ３ )、-S(=O) ２ NH ２ 、-SS(=O) ２ NH(CH) ３ )、-S(=O) ２ NH(CH) ２ CH ３ )、-S(=O) ２ N(CH) ３ ) ２ 、-NHSS(=O) ２ (CH) ３ )、-NHS(=O) ２ (CH) ２ CH ３ ) 【Chemistry 47】 Selected from, More specifically, R １ These are independently -H, -F, -Cl, and -CH ３ ien-CH ２ CH ３ , -CN, -COOH, -OH, -O-CH ３ , -O-CH ２ CH ３ , -SH, -S-CH ３ , -CF ３ ,-CHF ２ , -NH ２ ,-NH(CH ３ ), -N(CH ３ ) ２ , 【Chemistry 48】 -C(=0)NH ２ 、 【Chemistry 49】 Selected from, More preferably, R １ These are independently -H, -Cl, -OH, and -O-CH ３ ,-NH(CH ３ )or [Transformation 50] Selected from, A compound represented by formula (I) according to any one of claims 1 to 32, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

34. R １ These are independently -H, -Cl, -OH, and -O-CH ３ ,-NH(CH ３ )or 【Chemistry 51】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 33, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

35. R ２ These are, independently, hydrogen, -F, -Cl, -Br, and -C. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, Preferably, R ２ These are, independently, hydrogen, -F, -Cl, -Br, and -CH, respectively. ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 52】 -CH ２ F, -CHF ２ -CF ３ 、-CH ２ CH ２ F, -CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ -CF ２ CH ３ 、-CN、-NH ２ 、-NH(CH) ３ )、-N(CH ３ ) ２ 、-NH(CH) ２ CH ３ )、-OH、-O-CH ３ 、-O-CH ２ CH ３ 、-SH、-S-CH ３ 、-S-CH ２ CH ３ 、-S(=O)CH ３ 、-S(=O)(CH ２ CH ３ )、-S(=O) ２ CH ３ 、-SS(=O) ２ (CH) ２ CH ３ )、-COOH、-C(=O)(CH ３ )、-C(=O)(CH ２ CH ３ )、-C(=O)(OCH ３ )、-C(=O)(OCH ２ CH ３ )、-OC(=O)(CH ３ )、-OC(=O)(CH ２ CH ３ )、-C(=O)NH ２ 、-C(=O)NH(CH ３ )、-C(=O)NH(CH ２ CH ３ )、-C(=O)N(CH ３ ) ２ 、-NHC(=O)(CH ３ )、-NHC(=O)(CH ２ CH ３ )、-S(=O)NH ２ 、-S(=O)NH(CH ３ )、-S(=O)NH(CH ２ CH ３ )、-S(=O)N(CH ３ ) ２ 、-NHS(=O)(CH ３ )、-NHS(=O)(CH ２ CH ３ )、-S(=O) ２ (OCH ３ )、-S(=O) ２ (OCH ２ CH ３ )、-S(=O) ２ NH ２ 、-SS(=O) ２ NH(CH) ３ )、-S(=O) ２ NH(CH) ２ CH ３ )、-S(=O) ２ N(CH) ３ ) ２ 、-NHSS(=O) ２ (CH) ３ )、-NHS(=O) ２ (CH) ２ CH ３ ) 【Chemistry 53】 Selected from, More specifically, R ２ These are independently -H, -F, -Cl, and -CH ３ ien-CH ２ CH ３ , -CN, -COOH, -OH, -O-CH ３ , -O-CH ２ CH ３ , -SH, -S-CH ３ , -CF ３ ,-CHF ２ , -NH ２ ,-NH(CH ３ ), -N(CH ３ ) ２ , 【Chemistry 54】 -C(=0)NH ２ 、 【Transformation 55】 Selected from, More preferably, R ２ These are independently -H and -CH ３ or -CH ２ CH ３ Selected from, A compound represented by formula (I) according to any one of claims 1 to 34, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

36. R ２ These are independently -H and -CH ３ or -CH ２ CH ３ Selected from, A compound represented by formula (I) according to any one of claims 1 to 35, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

37. base 【Transformation 56】 teeth, 【Chemistry 57】 【Transformation 58】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 36, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

38. base 【Chemistry 59】 teeth, 【Transformation 60】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 36, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

39. Ring A is selected from a 3-7 membered carbon ring, a 3-7 membered heterocycle containing 1, 2, or 3 heteroatoms selected from N, O, or S, a benzene ring, or a 5-6 membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S. A compound represented by formula (I) according to any one of claims 1 to 38, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

40. Ring A is selected from a 3-membered carbon ring, a 4-membered carbon ring, a 5-membered carbon ring, a 6-membered carbon ring, a 7-membered carbon ring, a 3-membered heterocycle containing 1 or 2 heteroatoms selected from N, O, or S, a 4-membered heterocycle containing 1, 2, or 3 heteroatoms selected from N, O, or S, a 5-membered heterocycle containing 1, 2, or 3 heteroatoms selected from N, O, or S, a 6-membered heterocycle containing 1, 2, or 3 heteroatoms selected from N, O, or S, a benzene ring, a 5-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S, or a 6-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S. A compound represented by formula (I) according to any one of claims 1 to 39, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

41. Ring A is, 【Chemistry 61】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 40, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

42. Ring A is, 【Transformation 62】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 41, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

43. Ring A is, 【Transformation 63】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 42, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

44. The aforementioned compound is selected from formula (I-4), formula (I-5), or formula (I-6). 【Chemistry 64】 R Ｓ１ , n １ , ring B, R Ｓ２ , n ２ , R １ , R ２ and R ３ This is the same as the definition in claim 1. A compound represented by formula (I) according to any one of claims 1 to 43, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

45. R Ｓ１ These are halogen and -C, respectively, independently. １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, the -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～６ Alkoxy groups, 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups are halogens, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ It may be substituted with one or more substituents selected from a 3-7 membered cycloalkyl group, a 3-7 membered cycloalkenyl group, a 3-7 membered cycloalkynyl group, a 3-7 membered heterocyclic group, a 6-10 membered aryl group, or a 5-10 membered heteroaryl group. Preferably, R Ｓ１ These are independently -F, -Cl, -Br, and -C １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -C １～３ Alkylene group -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ , -C １～３ Alkylene group - NH ２ -OH, -O(C) １～３ Alkyl alkyl group), -O (halogenated C １～３ Alkyl alkyl group), -C １～３ Alkylene group -OH, -O (3-7 membered cycloalkyl group), -SH, -S (C １～３ Alkyl alkyl group), -C １～３ Alkylene group -SH, -C(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl alkyl group) C (=O) (C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O)(C) １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, More specifically, R Ｓ１ These are independently -F, -Cl, -Br, and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Transformation 65】 -CH ２ F, -CHF ２ -CF ３ 、-CH ２ CH ２ F, -CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ -CF ２ CH ３ 、-CN、-NH ２ 、-NH(CH) ３ )、-N(CH ３ ) ２ 、-NH(CH) ２ CH ３ )、-NH(CH(CH ３ ) ２ )、-OH、-O-CH ３ 、-O-CH ２ CH ３ 、-O-CH(CH ３ ) ２ 、-O-CHF ２ 、-O-CF ３ 、-SH、-S-CH ３ 、-S-CH ２ CH ３ 、-S-CH(CH ３ ) ２ 、-S(=O)CH ３ 、-S(=O)(CH ２ CH ３ )、-S(=O)(CH(CH ３ ) ２ )、-S(=O) ２ CH ３ 、-SS(=O) ２ (CH) ２ CH ３ )、-S(=O) ２ (CH(CH ３ ) ２ )、-COOH、-C(=O)(CH ３ )、-C(=O)(CH ２ CH ３ )、-C(=O)(CH(CH ３ ) ２ )、-C(=O)(CF ３ )、-C(=O)(OCH ３ )、-C(=O)(OCH ２ CH ３ )、-C(=O)(OCH(CH ３ ) ２ )、-OC(=O)(CH ３ )、-OC(=O)(CH ２ CH ３ )、-OC(=O)(CH(CH ３ ) ２ )、-C(=O)NH ２ 、-C(=O)NH(CH ３ )、-C(=O)NH(CH ２ CH ３ )、-C(=O)NH(CH(CH ３ ) ２ )、-C(=O)N(CH ３ ) ２ 、-C(=O)N(CH ２ CH ３ ) ２ 、-NHC(=O)(CH ３ )、-NHC(=O)(CH ２ CH ３ )、-NHC(=O)(CH(CH ３ ) ２ )、-N(CH ３ )C(=O)(CH ３ )、-S(=O)NH ２ 、-S(=O)NH(CH ３ )、-S(=O)NH(CH ２ CH ３ )、-S(=O)NH(CH(CH ３ ) ２ )、-S(=O)N(CH ３ ) ２ 、-S(=O)N(CH ３ (CH) ２ CH ３ )、-NHS(=O)(CH ３ )、-NHS(=O)(CH ２ CH ３ )、-NHS(=O)(CH(CH ３ ) ２ )、-N(CH ３ )S(=O)(CH ３ )、-S(=O) ２ NH ２ 、-SS(=O) ２ NH(CH) ３ )、-S(=O) ２ NH(CH ２ CH ３ )、-S(=O) ２ NH(CH(CH ３ ) ２ )、-S(=O) ２ N(CH ３ ) ２ 、-NHS(=O) ２ (CH ３ )、-NHS(=O) ２ (CH ２ CH ３ )、-NHS(=O) ２ (CH(CH ３ ) ２ )、-CH ２ -OH、-CH ２ CH ２ -OH、-CH(CH ３ )-OH、-CH ２ -SH、-CH ２ CH ２ -SH、-CH(CH ３ )-SH、-CH ２ -NH ２ 、-CH ２ CH ２ -NH ２ 、-CH(CH ３ )-NH ２ 、-CH ２ -CN、-CH ２ CH ２ -CN、-CH(CH ３ )-CN、 【Chemical Formula 66】 Selected from, More specifically, R Ｓ１ These are independently -F, -Cl, and -CH ３ ien-CH ２ CH ３ , -CN, -COOH, -CH ２ -OH, -CH ２ CH ２ -OH, -OH, -O-CH ３ , -O-CH ２ CH ３ , -CF ３ ,-CHF ２ , -NH ２ ,-NH(CH ３ ), -N(CH ３ ) ２ ,-NH(CH ２ CH ３ ), -CH ２ -NH ２ ien-CH ２ CH ２ -NH ２ , 【Transformation 67】 -O-CF ３ 、-O-CHF ２ 、-C(=O)NH ２ 、 【Transformation 68】 Selected from, More preferably, R Ｓ１ These are independently -F, -Cl, -CN, and -CF ３ ien-CH ３ ien-CH ２ CH ３ , -O-CH ３ , -O-CH ２ CH ３ or -O-CF ３ Selected from, n １ n is selected from 0, 1, 2, 3, 4, 5 or 6. １ n is selected from 0, 1, 2, 3 or 4. １ is selected from 0, 1, 2, or 3. A compound represented by formula (I) according to any one of claims 1 to 44, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

46. base 【Transformation 69】 teeth, 【Transformation 70】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 45, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

47. base 【Chemistry 71】 teeth, 【Chemistry 72】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 46, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

48. Ring B is selected from a benzene ring or a 5- to 10-membered heteroaromatic ring containing 1, 2, 3, 4, 5, or 6 heteroatoms selected from N, O, or S. A compound represented by formula (I) according to any one of claims 1 to 47, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

49. Ring B is selected from a benzene ring, a five-membered heteroaromatic ring containing one, two, or three heteroatoms selected from N, O, or S, a six-membered heteroaromatic ring containing one, two, or three heteroatoms selected from N, O, or S, a seven-membered heteroaromatic ring containing one, two, or three heteroatoms selected from N, O, or S, an eight-membered heteroaromatic ring containing one, two, or three heteroatoms selected from N, O, or S, a nine-membered heteroaromatic ring containing one, two, or three heteroatoms selected from N, O, or S, and a ten-membered heteroaromatic ring containing one, two, or three heteroatoms selected from N, O, or S. A compound represented by formula (I) according to any one of claims 1 to 48, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

50. Ring B is, 【Transformation 73】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 49, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

51. Ring B is, 【Chemistry 74】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 50, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

52. R Ｓ２ These are halogen and -C, respectively, independently. １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, the -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～６ Alkoxy groups, 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups are halogens, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl alkyl group), one or more -O (C １～６ -O(C) substituted with alkyl group １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ It may be substituted with one or more substituents selected from a 3-7 membered cycloalkyl group, a 3-7 membered cycloalkenyl group, a 3-7 membered cycloalkynyl group, a 3-7 membered heterocyclic group, a 6-10 membered aryl group, or a 5-10 membered heteroaryl group. Preferably, R Ｓ２ These are independently -F, -Cl, -Br, and -C １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, one or more (one or more -O(C) １～６ -O(C) substituted with alkyl group １～６ -C substituted with an alkyl group １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -C １～３ Alkylene group -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ , -C １～３ Alkylene group - NH ２ -OH, -O(C) １～３ Alkyl alkyl group), -C １～３ Alkylene group -OH, -O (3-7 membered cycloalkyl group), -SH, -S (C １～３ Alkyl alkyl group), -C １～３ Alkylene group -SH, -C(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl alkyl group) C (=O) (C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O)(C) １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, More specifically, R Ｓ２ These are independently -F, -Cl, -Br, and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 75】 -CH ２ F、-CHF ２ 、-CF ３ 、-CH ２ CH ２ F、-CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ 、-CF ２ CH ３ 、-CN、-NH ２ 、-NH(CH ３ )、-N(CH ３ ) ２ 、-NH(CH ２ CH ３ )、-NH(CH(CH ３ ) ２ )、-OH、-O-CH ３ 、-O-CH ２ CH ３ 、-O-CH(CH ３ ) ２ 、-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ３ 、-CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ３ 、-CH ２ -O-CH ２ -O-CH ２ -O-CH ３ 、-CH ２ -O-CH ２ -O-CH ２ -O-CH ２ CH ３ 、-O-CHF ２ 、-O-CF ３ 、-SH、-S-CH ３ 、-S-CH ２ CH ３ 、-S-CH(CH ３ ) ２ 、-S(=O)CH ３ 、-S(=O)(CH ２ CH ３ )、-S(=O)(CH(CH ３ ) ２ )、-S(=O) ２ CH ３ 、-SS(=O) ２ (CH2CH) ３ )、-S(=O) ２ (CH(CH ３ ) ２ )、-COOH、-C(=O)(CH ３ )、-C(=O)(CH ２ CH ３ )、-C(=O)(CH(CH ３ ) ２ )、-C(=O)(CF ３ )、-C(=O)(OCH ３ )、-C(=O)(OCH ２ CH ３ )、-C(=O)(OCH(CH ３ ) ２ )、-OC(=O)(CH ３ )、-OC(=O)(CH ２ CH ３ )、-OC(=O)(CH(CH ３ ) ２ )、-C(=O)NH ２ 、-C(=O)NH(CH ３ )、-C(=O)NH(CH ２ CH ３ )、-C(=O)NH(CH(CH ３ ) ２ )、-C(=O)N(CH ３ ) ２ 、-C(=O)N(CH ２ CH ３ ) ２ 、-NHC(=O)(CH ３ )、-NHC(=O)(CH ２ CH ３ )、-NHC(=O)(CH(CH ３ ) ２ )、-N(CH ３ )C(=O)(CH ３ )、-S(=O)NH ２ 、-S(=O)NH(CH ３ )、-S(=O)NH(CH ２ CH ３ )、-S(=O)NH(CH(CH ３ ) ２ )、-S(=O)N(CH ３ ) ２ 、-S(=O)N(CH ３ )(CH ２ CH ３ )、-NHS(=O)(CH ３ )、-NHS(=O)(CH ２ CH ３ )、-NHS(=O)(CH(CH ３ ) ２ )、-N(CH ３ )S(=O)(CH ３ )、-S(=O) ２ NH ２ 、-S(=O) ２ NH(CH ３ )、-S(=O) ２ NH(CH ２ CH ３ )、-S(=O) ２ NH(CH(CH ３ ) ２ )、-S(=O) ２ N(CH ３ ) ２ 、-NHS(=O) ２ (CH ３ )、-NHS(=O) ２ (CH ２ CH ３ )、-NHS(=O) ２ (CH(CH ３ ) ２ )、-CH ２ -OH、-CH ２ CH ２ -OH、-CH(CH ３ )-OH、-CH ２ -SH、-CH ２ CH ２ -SH、-CH(CH ３ )-SH、-CH ２ -NH ２ 、-CH ２ CH ２ -NH ２ 、-CH(CH ３ )-NH ２ 、-CH ２ -CN、-CH ２ CH ２ -&N、-CH (CH ３ )-CN、 【Transformation 76】 Selected from, More specifically, R Ｓ２ These are independently -F, -Cl, and -CH ３ ien-CH ２ CH ３ , -CN, -COOH, -CH ２ -OH, -CH ２ CH ２ -OH, -OH, -O-CH ３ , -O-CH ２ CH ３ ien-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ３ ien-CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ３ ien-CH ２ -O-CH ２ -O-CH ２ -O-CH ３ ien-CH ２ -O-CH ２ -O-CH ２ -O-CH ２ CH ３ , -CF ３ ,-CHF ２ , -NH ２ ,-NH(CH ３ ), -N(CH ３ ) ２ ,-NH(CH ２ CH ３ ), -CH ２ -NH ２ ien-CH ２ CH ２ -NH ２ , 【Chemical 77】 -O-CF ３ 、-O-CHF ２ 、-C(=O)NH ２ 、 【Transformation 78】 Selected from, More preferably, R Ｓ２ These are independently -F, -Cl, and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ OH, -CH ２ CH ２ OCH ２ CH ２ OCH ２ CH ２ OCH ３ Or selected from -OH, n ２ n is selected from 0, 1, 2, 3, 4, 5 or 6. ２ n is selected from 0, 1, 2, 3 or 4. ２ is selected from 0, 1, 2, or 3. A compound represented by formula (I) according to any one of claims 1 to 51, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

53. The aforementioned compound is selected from formula (I-7), formula (I-8), or formula (I-9). 【Transformation 79】 R ８ Each time it appears, hydrogen, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -C(=O)R ８６ , -C (=O) OR ８２ , -C(=O)NR ８３ R ８４ , -S(=O)R ８７ , -S (=O) OR ８２ , -S(=O)NR ８３ R ８４ , -S (=O) ２ R ８８ , -S (=O) ２ OR ８２ , -S (=O) ２ NR ８３ R ８４ , -P (=O) (R ８９ ) ２ , selected from a 3-14 membered carbon ring group, a 3-14 membered heterocyclic group, a 6-14 membered aryl group, or a 5-14 membered heteroaryl group, provided that the -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy groups, 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-14 membered aryl groups, or 5-14 membered heteroaryl groups are independently halogens and -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～１０ Alkyl alkyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkoxy group, -CN, -NO ２ , -N ３ , oxo, -OR １０ｂ , -NR １０ｃ R １０ｄ , -SR １０ｅ , -C(=O)R １０ｆ 、-C(=O)OR １０ｂ 、-OC(=O)R １０ｆ 、-OC(=O)OR １０ｂ 、-C(=O)NR １０ｃ R １０ｄ 、-OC(=O)NR １０ｃ R １０ｄ 、-C(=NR １０ｃ )R １０ａ 、-C(=NR １０ｃ )NR １０ｃ R １０ｄ 、-NR １０ｃ C(=NR １０ｃ )NR １０ｃ R １０ｄ 、-NR １０ｃ C(=O)R １０ｆ 、-NR １０ｃ C(=O)OR １０ｂ 、-NR １０ｃ C(=O)NR １０ｃ R １０ｄ 、-S(=O)R １０ｇ 、-S(=O)OR １０ｂ 、-OS(=O)R １０ｇ 、-OS(=O)OR １０ｂ 、-S(=O)NR １０ｃ R １０ｄ 、-NR １０ｃ S(=O)R １０ｇ 、-NR １０ｃ S(=O)OR １０ｂ 、-OS(=O)NR １０ｃ R １０ｄ 、-NR １０ｃ S(=O)NR １０ｃ R １０ｄ 、-S(=O) ２ R １０ｈ 、-S(=O) ２ OR １０ｂ 、-OS(=O) ２ R １０ｈ 、-OS(=O) ２ OR １０ｂ 、-S(=O) ２ NR １０ｃ R １０ｄ 、-NR １０ｃ S(=O) ２ R １０ｈ 、-NR １０ｃ S(=O) ２ OR １０ｂ 、-OS(=O) ２ NR １０ｃ R １０ｄ , -NR １０ｃ S (=O) ２ NR １０ｃ R １０ｄ , -P (=O) (R １０ｉ ) ２ They may be substituted with one or more substituents selected from a 3-14 member cycloalkyl group, a 3-14 member heterocyclic group, a 6-12 member aryl group, or a 5-14 member heteroaryl group. R ８２ Each time it appears, hydrogen, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -C(=O)R ７ｆ , -C (=O) OR ７ｂ , -S(=O)R ７ｇ , -S (=O) OR ７ｂ , -S (=O) ２ R ７ｈ , -S (=O) ２ OR ７ｂ , -P (=O) (R ７ｉ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups, R ８３ or R ８４ Each time it appears, hydrogen, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -C(=O)R ８ｆ , -C (=O) OR ８ｂ , -C(=O)NR ８ｃ R ８ｄ , -S(=O)R ８ｇ , -S (=O) OR ８ｂ , -S(=O)NR ８ｃ R ８ｄ , -S (=O) ２ R ８ｈ , -S (=O) ２ OR ８ｂ , -S (=O) ２ NR ８ｃ R ８ｄ , -P (=O) (R ８ｉ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-14 membered aryl groups, or 5-14 membered heteroaryl groups, R ８６ , R ８７ , R ８８ or R ８９ Each time it appears, it is hydrogen, halogen, -C １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -OR ９ｂ , -NR ９ｃ R ９ｄ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-14 membered aryl groups, or 5-14 membered heteroaryl groups, Preferably, (R ８３ and R ８４ These two elements, together with the nitrogen atom linked to them, form a 3-14 membered heterocyclic base ring or a 5-14 membered heteroaromatic ring, and the 3-14 membered heteroaromatic ring consists of 1, 2, 3, 4, 5, or 6 N, O, S, SO or SO ２ The heteroatom is selected from, and the 3- to 14-membered heteroaromatic ring contains 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O, and S, and each of the rings independently contains n ６ Individual R Ｓ４ It may also be replaced with R １０ａ Each instance, it independently produces hydrogen, halogen, and -C. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～１０ Alkoxy group, -OR Ｚ１ｂ , -NR Ｚ１ｃ R Ｚ１ｄ , -SR Ｚ１ｅ , -C(=O)R Ｚ１ｆ , -C (=O) OR Ｚ１ｂ -OC(=O)R Ｚ１ｆ , -OC(=O)OR Ｚ１ｂ , -C(=O)NR Ｚ１ｃ R Ｚ１ｄ , -OC(=O)NR Ｚ１ｃ R Ｚ１ｄ , -C(=NR Ｚ１ｃ ) R Ｚ１ａ , -C(=NR Ｚ１ｃ ) NR Ｚ１ｃ R Ｚ１ｄ , -NR Ｚ１ｃ C (=NR Ｚ１ｃ ) NR Ｚ１ｃ R Ｚ１ｄ , -NR Ｚ１ｃ C(=O)R Ｚ１ｆ , -NR Ｚ１ｃ C (=O) OR Ｚ１ｂ , -NR Ｚ１ｃ C(=O)NR Ｚ１ｃ R Ｚ１ｄ , -S(=O)R Ｚ１ｇ , -S (=O) OR Ｚ１ｂ , -OS(=O)R Ｚ１ｇ , -OS(=O)OR Ｚ１ｂ , -S(=O)NR Ｚ１ｃ R Ｚ１ｄ , -NR Ｚ１ｃ S(=O)R Ｚ１ｇ , -NR Ｚ１ｃ S (= O) OR Ｚ１ｂ , -OS(=O)NR Ｚ１ｃ R Ｚ１ｄ , -NR Ｚ１ｃ S(=O)NR Ｚ１ｃ R Ｚ１ｄ , -S (=O) ２ R Ｚ１ｈ , -S (=O) ２ OR Ｚ１ｂ , -OS (=O) ２ R Ｚ１ｈ , -OS (=O) ２ OR Ｚ１ｂ , -S (=O) ２ NR Ｚ１ｃ R Ｚ１ｄ , -NR Ｚ１ｃ S (=O) ２ R Ｚ１ｈ , -NR Ｚ１ｃ S (=O) ２ OR Ｚ１ｂ , -OS (=O) ２ NR Ｚ１ｃ R Ｚ１ｄ , -NR Ｚ１ｃ S (=O) ２ NR Ｚ１ｃ R Ｚ１ｄ , -P (=O) (R Ｚ１ｉ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups, R １０ｂ or R １０ｅ Each instance, hydrogen and -C appear independently. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -C(=O)R Ｚ２ｆ , -C (=O) OR Ｚ２ｂ , -S(=O)R Ｚ２ｇ , -S (=O) OR Ｚ２ｂ , -S (=O) ２ R Ｚ２ｈ , -S (=O) ２ OR Ｚ２ｂ , -P (=O) (R Ｚ２ｉ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups, R １０ｃ or R １０ｄ Each instance, hydrogen and -C appear independently. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -C(=O)R Ｚ３ｆ , -C(=O)NR Ｚ３ｃ R Ｚ３ｄ , -S(=O)R Ｚ３ｇ , -S(=O)NR Ｚ３ｃ R Ｚ３ｄ , -S (=O) ２ R Ｚ３ｈ , -S (=O) ２ NR Ｚ３ｃ R Ｚ３ｄ , -P (=O) (R Ｚ３ｉ ) ２ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups, R １０ｆ , R １０ｇ , R １０ｈ or R １０ｉ Each instance, it independently produces hydrogen, halogen, and -C. １～１０ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～１０ Alkoxy group, halogenated C １～１０ Alkyl alkyl groups, halogenated C １～１０ Alkoxy group, -OR Ｚ４ｂ , -NR Ｚ４ｃ R Ｚ４ｄ , selected from 3-14 membered carbon ring groups, 3-14 membered heterocyclic groups, 6-12 membered aryl groups, or 5-14 membered heteroaryl groups, (R １０ｃ and R １０ｄ These two elements, together with the nitrogen atom linked to them, form a 3-14 membered heterocyclic base ring or a 5-14 membered heteroaromatic ring, and the 3-14 membered heteroaromatic ring consists of 1, 2, 3, 4, 5, or 6 N, O, S, SO or SO ２ The heteroatom is selected from, and the 3- to 14-membered heteroaromatic ring contains 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O, and S, and each of the rings independently contains n ７ Individual R Ｓ５ It may also be replaced with n ６ , R Ｓ４ , R Ｚ１ａ , R Ｚ１ｂ , R Ｚ１ｃ , R Ｚ１ｄ , R Ｚ１ｅ , R Ｚ１ｆ , R Ｚ１ｇ , R Ｚ１ｈ , R Ｚ１ｉ , R Ｚ２ｆ , R Ｚ２ｂ , R Ｚ２ｇ , R Ｚ２ｈ , R Ｚ２ｉ , R Ｚ３ｆ , R Ｚ３ｃ , R Ｚ３ｄ , R Ｚ３ｇ , R Ｚ３ｈ , R Ｚ３ｉ , R Ｚ４ｂ , R Ｚ４ｃ , R Ｚ４ｄ , R Ｓ５ and n ７ This is the same as the definition in claim 1, n ５ is selected from 0, 1, or 2. R Ｓ１ , n １ , R Ｓ２ , R １ , R ２ and R ３ This is the same as the definition in claim 1. A compound represented by formula (I) according to any one of claims 1 to 52, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

54. R ８ These are hydrogen and -C, respectively, independently. １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, one or more (one or more -O(C) １～６ -O(C) substituted with alkyl group １～６ -C substituted with an alkyl group １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -C １～６ Alkylene group -OH, -C (=O) (C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, phenyl groups, or 5-10 membered heteroaryl groups, Preferably, R ８ These are hydrogen and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C １～３ Alkylene group -OH, -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , 3-7 member cycloalkyl groups, -C １～３ Alkoxy group, 0, 1 or 2 (1-territory-O(C) １～３ -O(C) substituted with alkyl group １～３ -C substituted with an alkyl group １～３ Selected from alkoxy groups, More specifically, R ８ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 80】 -CH ２ F、-CHF ２ 、-CF ３ 、-CH ２ CH ２ F、-CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ 、-CF ２ CH ３ 、-CH ２ CH ２ OH、-CH ２ OH、-CH(CH ２ ) ３ OH、-C(=O)(CH ３ )、-C(=O)(CH ２ CH ３ )、-C(=O)(CH(CH ３ ) ２ )、-S(=O)CH ３ 、-S(=O)(CH ２ CH ３ )、-S(=O)(CH(CH ３ ) ２ )、-S(=O) ２ CH ３ 、-S(=O) ２ (CH ２ CH ３ )、-S(=O) ２ (CH(CH ３ ) ２ )、 【Chemistry 81】 -O-CH ３ 、-O-CH ２ CH ３ 、-O-CH(CH ３ ) ２ 、-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ３ 、-CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ３ 、-CH ２ -O-CH ２ -O-CH ２ -O-CH ３ Or -CH ２ -O-CH ２ -O-CH ２ -O-CH ２ CH ３ selected from, More specifically, R ８ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ ien-CH ２ CH ２ OH, -CH ２ OH, -CH(CH ２ ) ３ OH or -CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ３ Selected from, More preferably, R ８ Each of them is independently -CH ３ Selected from, A compound represented by formula (I) according to claim 53, its stereoisomer, its tautomer, its atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer or a pharmaceutically acceptable salt of its atropisomer.

55. The aforementioned compound is selected from formula (I-10), formula (I-11), or formula (I-12). 【Chemistry 82】 n ５ is selected from 0, 1, or 2. R Ｓ１ , n １ , R Ｓ２ , R １ , R ２ and R ３ This is the same as the definition in claim 1. A compound represented by formula (I) according to any one of claims 1 to 54, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

56. base 【Chemistry 83】 teeth, 【Chemical 84】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 55, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

57. base 【Chemical 85】 teeth, 【Chemical 86】 Selected from, Preferably, 【Transformation 87】 teeth, 【Chemical 88】 Selected from, A compound represented by formula (I) according to any one of claims 1 to 56, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof. [Request Item 58] [Chemistry 89] however, Y １ is -O-, -NR Ｙ１３ -, -S-, *-NR Ｙ１３ -C(=O)-, *-NR Ｙ１３ S (=O) - or * - NR Ｙ１３ S (=O) ２ - Selected from, * is the base [Chemical 90] It shows the connection point with, R Ｙ１３ is hydrogen, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, halogenated C １～６ Alkyl alkyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkoxy group, -C(=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from a 3-10 membered carbon ring group, a 3-10 membered heterocyclic group, a phenyl group, a naphthyl group, or a 5-10 membered heteroaryl group, n ４ is selected from 0, 1, 2, or 3. X １ is N or CR ３ Selected from, R １ These are, independently, hydrogen, -F, -Cl, -Br, and -C. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, phenyl groups, naphthyl groups, or 5-10 membered heteroaryl groups, R ２ These are, independently, hydrogen, -F, -Cl, -Br, and -C. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, R ３ These are, independently, hydrogen, -F, -Cl, -Br, and -C. １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ (Alkyl alkyl group), - (C １～３ (Alkylene group)-C(=O)R ６ , -C(=O)R ６ -OC(=O)R ６ , -NHC(=O)R ６ , -N(C １～３ (Alkyl alkyl group) C(=O)R ６ , -S(=O)R ６ , -NHS(=O)R ６ , -N(C １～３ Alkyl(S)(=O)R ６ , -S (=O) ２ R ６ , -NHS (=O) ２ R ６ , -N(C １～３ Alkyl(S)(=O) ２ R ６ , selected from a 3-7 membered carbon ring group, a 3-7 membered heterocyclic group, a phenyl group, a naphthyl group, or a 5-10 membered heteroaryl group, the -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy groups, 3-7 membered carbon ring groups, 3-7 membered heterocyclic groups, phenyl groups, naphthyl groups, or 5-10 membered heteroaryl groups are halogens, -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkyl, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -C (=O) (OC １～３ Alkyl alkyl group) or -C (=O) (halogenated C １～３ It may be substituted with one or more substituents selected from alkyl groups. R ６ is hydrogen, -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -OH, -O(C) １～３ Alkyl(Hydrogen), -NH2, -NH(C １～４ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ , a 3-7 membered carbon ring group, a 3-7 membered heterocyclic group, a phenyl group, a naphthyl group, or a 5-10 membered heteroaryl group, and the R ６ is one or more R ６Ａ It may be replaced by the above R ６Ａ Each instance, halogen and -C are independently identified. １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～４ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered carbon ring groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, R ６Ａ The aforementioned (-C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy groups, 3-7 membered carbon ring groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups are halogens, -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkyl, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -C (=O) (halogenated C １～３ Alkyl alkyl group), -Si (C １～３ (Alkyl group) ３ They may be substituted with one or more substituents selected from the following: R ４ or R ５ Each instance of these elements independently represents hydrogen, -F, -Cl, -Br, and -C. １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, Ring A is selected from a 3-7 membered carbon ring, a 3-7 membered heterocycle containing 1, 2 or 3 heteroatoms selected from N, O or S, a benzene ring, or a 5-6 membered heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from N, O or S. Ring B is selected from a benzene ring or a 5- to 10-membered heteroaromatic ring containing 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O or S. R Ｓ１ These are halogen and -C, respectively, independently. １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, the -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～６ Alkoxy groups, 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups are halogens, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ It may be substituted with one or more substituents selected from a 3-7 membered cycloalkyl group, a 3-7 membered cycloalkenyl group, a 3-7 membered cycloalkynyl group, a 3-7 membered heterocyclic group, a 6-10 membered aryl group, or a 5-10 membered heteroaryl group. R Ｓ２ These are halogen and -C, respectively, independently. １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ , selected from 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, the -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～６ Alkoxy groups, 3-7 membered cycloalkyl groups, 3-7 membered cycloalkenyl groups, 3-7 membered cycloalkynyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups are halogens, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C ２～６ Alkenyl group, halogenated C ２～６ Alkynyl group, halogenated C １～６ Alkoxy group, -CN, -NH ２ ,-NH(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl group) ２ -OH, -O(C) １～６ Alkyl alkyl group), one or more -O (C １～６ -O(C) substituted with alkyl group １～６ Alkyl(alkyl group), -SH, -S(C １～６ Alkyl alkyl group), -C (=O) (C １～６ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～６ Alkyl alkyl group), -OC (=O)(C １～６ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～６ Alkyl alkyl group), -C(=O)N(C １～６ (Alkyl group) ２ , -NHC(=O)(C １～６ Alkyl alkyl group), -N(C １～６ (Alkyl alkyl group) C (=O) (C １～６ Alkyl alkyl group), -NHC(=O)NH ２ , -NHC(=O)NH(C １～６ Alkyl alkyl group), -NHC(=O)N(C １～６ (Alkyl group) ２ , -N(C １～６ Alkyl(C)(=O)NH ２ , -N(C １～６ Alkyl(C)(=O)NH(C) １～６ Alkyl alkyl group), -N(C １～６ Alkyl(C)C(=O)N(C) １～６ (Alkyl group) ２ , -S (=O) (C １～６ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～６ Alkyl(alkyl group), -S(=O)N(C) １～６ (Alkyl group) ２ , -NHS(=O)(C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O)(C) １～６ Alkyl(alkyl group), -S (=O) ２ (C １～６ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～６ Alkyl(alkyl group), -S (=O) ２ N(C) １～６ (Alkyl group) ２ , -NHS (=O) ２ (C １～６ Alkyl alkyl group), -N(C １～６ Alkyl(S)(=O) ２ (C １～６ Alkyl(alkyl group), -P(=O)H(C １～６ Alkyl alkyl group), -P (=O)(C １～６ (Alkyl group) ２ It may be substituted with one or more substituents selected from a 3-7 membered cycloalkyl group, a 3-7 membered cycloalkenyl group, a 3-7 membered cycloalkynyl group, a 3-7 membered heterocyclic group, a 6-10 membered aryl group, or a 5-10 membered heteroaryl group. n １ is selected from 0, 1, 2, 3, 4, 5 or 6. n ２ is selected from 0, 1, 2, 3, 4, 5, or 6. A compound represented by formula (I) according to any one of claims 1 to 57, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

59. The aforementioned compound is selected from formula (II), 【Chemistry 91】 Y １ is, -NR Ｙ１３ - or * - NR Ｙ１３ -C (=O)- is selected, and * is the base 【Chemistry 92】 It shows the connection point with, R Ｙ１３ These are independently -H or -C １～３ Selected from alkyl groups, preferably R Ｙ１３ Each is independently selected from -H, n ４ n is selected from 0, 1, or 2, preferably n ４ This is selected from 0 or 1. Ring A is selected from a 3-7 membered carbon ring, a 3-7 membered heterocycle containing 1, 2 or 3 heteroatoms selected from N, O or S, a benzene ring, or a 5-6 membered heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from N, O or S, preferably, Ring A is selected from a 5 membered carbon ring, a 6 membered carbon ring, a 5 membered heterocycle containing 1, 2 or 3 heteroatoms selected from N, O or S, a 6 membered heterocycle containing 1, 2 or 3 heteroatoms selected from N, O or S, a benzene ring, a 5 membered heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from N, O or S, or a 6 membered heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from N, O or S, more preferably, Ring A is 【Chemistry 93】 Selected from, and more preferably, ring A is 【Chemical 94】 Selected from, R Ｓ１ These are independently -F, -Cl, -Br, and -C １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -C １～３ Alkylene group -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ , -C １～３ Alkylene group - NH ２ -OH, -O(C) １～３ Alkyl alkyl group), -O (halogenated C １～３ Alkyl alkyl group), -C １～３ Alkylene group -OH, -O (3-7 membered cycloalkyl group), -SH, -S (C １～３ Alkyl alkyl group), -C １～３ Alkylene group -SH, -C(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl alkyl group) C (=O) (C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O)(C) １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, preferably R Ｓ１ These are halogen, -CN, and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -OH, -O(C) １～３ (Alkyl alkyl group) or -O (Halogenated C １～３ Selected from alkyl groups, more preferably R Ｓ１ These are independently -F, -Br, -Cl, -CN, and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ ien-CH ２ F, -CHF ２ , -CF ３ ien-CH ２ CH ２ F, -CH ２ CHF ２ ien-CH ２ CF ３ yan-CHFCH ３ , -CF ２ CH ３ , -OH, -O-CH ３ , -O-CH ２ CH ３ , -OCH ２ CH ２ CH ３ , -OCH(CH ３ ) ２ , -O-CF ３ , -O-CH ２ F, -O-CHF ２ , -O-CF ３ , -O-CH ２ CH ２ F, -O-CH ２ CHF ２ , -O-CH ２ CF ３ , -O-CHFCH ３ , -O-CF ２ CH ３ Selected from, and more preferably R Ｓ１ These are independently -F, -Cl, -CN, and -CF ３ ien-CH ３ ien-CH ２ CH ３ , -O-CH ３ , -O-CH ２ CH ３ or -O-CF ３ Selected from, n １ n is selected from 0, 1, 2, 3 or 4, preferably n １ is selected from 0, 1, 2, or 3. R １ These are hydrogen, halogen, and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, phenyl groups, naphthyl groups, or 5-10 membered heteroaryl groups, preferably R １ These are, independently, hydrogen, halogen, -OH, and -O(C) １～３ Alkyl(alkyl group), -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ Or selected from a 3- to 7-membered heterocyclic group containing one, two, or three heteroatoms selected from N, O, or S, more preferably R １ These are independently -H, -F, -Br, -Cl, -OH, -O-CH ３ , -O-CH ２ CH ３ , -OCH ２ CH ２ CH ３ , -OCH(CH ３ ) ２ , -NH ２ ,-NH(CH ３ ), -N(CH ３ ) ２ ,-NH(CH ２ CH ３ ) or selected from a 3- to 7-membered heterocyclic group containing one, two or three heteroatoms selected from N, O or S, wherein the 3- to 7-membered heterocyclic group is 【Chemical 95】 Selected from, and more preferably R １ These are independently -H, -Cl, -OH, and -O-CH ３ ,-NH(CH ３ )or 【Chemistry 96】 Selected from, R ２ These are hydrogen, halogen, and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, preferably R ２ These are hydrogen and -C, respectively, independently. １～３ Selected from alkyl groups, more preferably R ２ These are independently -H and -CH ３ ien-CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, R ４ or R ５ Each instance of these elements independently represents hydrogen, -F, -Cl, -Br, and -C. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, preferably R ４ or R ５ Each instance of these elements independently represents hydrogen, -F, -Cl, -Br, and -C. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Selected from an alkynyl group and a 3- to 7-membered cycloalkyl group, more preferably R ４ or R ５ Each instance independently represents hydrogen, -F, -Cl, -Br, and -CH. ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 97】 -CH ２ F-CHF ２ 、-CF ３ 、-CH ２ CH ２ F-CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ 、-CF ２ CH ３ 、-CH ２ OCH ３ 、-CH ２ OCH ２ CH ３ 、 【Chem.98】 Selected from, more preferably, R ４ or R ５ Each instance of these is independently -H and -CH. ３ or -CH ２ CH ３ Selected from, and more preferably R ４ or R ５ Each time it appears, it is independently selected from -H, Ring B is selected from a benzene ring or a 5- to 10-membered heteroaromatic ring containing 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O or S, preferably, ring B is 【Chem.99】 Selected from, more preferably, ring B is 【Chemistry 100】 Selected from, R Ｓ２ These are halogen and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, one or more (one or more -O(C) １～３ -O(C) substituted with alkyl group １～３ -C substituted with an alkyl group １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -C １～３ Alkylene group -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ , -C １～３ Alkylene group - NH ２ -OH, -O(C) １～３ Alkyl alkyl group), -C １～３ Alkylene group -OH, -O (3-7 membered cycloalkyl group), -SH, -S (C １～３ Alkyl alkyl group), -C １～３ Alkylene group -SH, -C(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl alkyl group) C (=O) (C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O)(C) １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, preferably R Ｓ２ These are halogen and -C, respectively, independently. １～３ alkyl group, -OH, -C １～３ Alkylene group -OH, -O(C) １～３ Alkyl alkyl group), 1, 2 or 3 (1 or more -O(C) １～３ -O(C) substituted with alkyl group １～３ -C substituted with an alkyl group １～３ Selected from alkoxy groups, more preferably R Ｓ２ These are independently -F, -Br, -Cl, and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ ien-CH ２ -OH, -CH ２ CH ２ -OH, -OH, -O-CH ３ , -O-CH ２ CH ３ , -O-CH(CH ３ ) ２ ien-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ３ ien-CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ３ ien-CH ２ -O-CH ２ -O-CH ２ -O-CH ３ ien-CH ２ -O-CH ２ -O-CH ２ -O-CH ２ CH ３ Selected from, and more preferably R Ｓ２ These are independently -F, -Cl, and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ OH, -CH ２ CH ２ OCH ２ CH ２ OCH ２ CH ２ OCH ３ Or selected from -OH, n ２ n is selected from 0, 1, 2, 3 or 4, preferably n ２ is selected from 0, 1, 2, or 3. A compound represented by formula (I) according to any one of claims 1 to 58, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

60. The aforementioned compound is selected from formula (II-1) 【Chemistry 101】 however, R Ｙ１３ These are independently -H or -C １～３ Selected from alkyl groups, preferably R Ｙ１３ Each is independently selected from -H, Ring B is selected from a benzene ring or a 5-6 membered heteroaromatic ring containing 1, 2, 3, 4, 5 or 6 heteroatoms selected from N, O or S, preferably, ring B is 【Chemical Engineering 102】 Selected from, more preferably, ring B is 【Chemistry 103】 Selected from, R １ , R ２ , R ４ , R ５ , ring A, R Ｓ１ , n １ , R Ｓ２ , n ２ This is the same as the definition in claim 59. A compound represented by formula (I) according to any one of claims 1 to 59, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

61. The aforementioned compound is selected from formula (II-1-1), 【Chemical 104】 however, R Ｙ１３ These are independently -H or -C １～３ Selected from alkyl groups, preferably R Ｙ１３ These are independently -H and -CH ３ ien-CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, more preferably, R Ｙ１３ Each is independently selected from -H, R ８ These are hydrogen and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C １～３ Alkylene group -OH, -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , 3-7 member cycloalkyl groups, -C １～３ Alkoxy group, 0, 1 or 2 (1-territory-O(C) １～３ -O(C) substituted with alkyl group １～３ -C substituted with an alkyl group １～３ Selected from alkoxy groups, preferably R ８ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 105】 -CH ２ F、-CHF ２ 、-CF ３ 、-CH ２ CH ２ F、-CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ 、-CF ２ CH ３ 、-CH ２ CH ２ OH、-CH ２ OH、-CH(CH ２ ) ３ OH、-C(=O)(CH ３ )、-C(=O)(CH ２ CH ３ )、-C(=O)(CH(CH ３ ) ２ )、-S(=O)CH ３ 、-S(=O)(CH ２ CH ３ )、-S(=O)(CH(CH ３ ) ２ )、-S(=O) ２ CH ３ 、-S(=O) ２ (CH2CH ３ )、-S(=O) ２ (CH(CH ３ ) ２ )、 【Chemistry 106】 -O-CH ３ , -O-CH ２ CH ３ , -O-CH(CH ３ ) ２ ien-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ３ ien-CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ３ ien-CH ２ -O-CH ２ -O-CH ２ -O-CH ３ or -CH ２ -O-CH ２ -O-CH ２ -O-CH ２ CH ３ Selected from, more preferably, R ８ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ ien-CH ２ CH ２ OH, -CH ２ OH, -CH(CH ２ ) ３ OH or -CH ２ CH ２ -O-CH ２ CH ２ -O-CH ２ CH ２ -O-CH ３ Selected from, and more preferably R ８ Each of them is independently -CH ３ Selected from, R Ｓ２ These are independently -F, -Cl, -Br, and -C １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, one or more (one or more -O(C) １～６ -O(C) substituted with alkyl group １～６ -C substituted with an alkyl group １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -C １～３ Alkylene group -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ , -C １～３ Alkylene group - NH ２ -OH, -O(C) １～３ Alkyl alkyl group), -C １～３ Alkylene group -OH, -O (3-7 membered cycloalkyl group), -SH, -S (C １～３ Alkyl alkyl group), -C １～３ Alkylene group -SH, -C(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl alkyl group) C (=O) (C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O)(C) １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, preferably R Ｓ２ Each of them is independently -C １～３ Selected from alkyl groups, more preferably R Ｓ２ Each of them is independently -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, and more preferably R Ｓ２ Each of them is independently -CH ３ Selected from, n ５ is selected from 0, 1, or 2. R １ , R ２ , R ４ , R ５ , R Ｓ１ and n １ This is the same as the definition in claim 59. A compound represented by formula (I) according to any one of claims 1 to 60, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

62. The aforementioned compound is selected from formula (II-2), 【Chemistry 107】 R Ｙ１３ These are independently -H or -C １～３ Selected from alkyl groups, preferably R Ｙ１３ These are independently -H and -CH ３ ien-CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, more preferably, R Ｙ１３ Each is independently selected from -H, n ４ n is selected from 0, 1, or 2, preferably n ４ This is selected from 0 or 1. R １ These are hydrogen, halogen, and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, phenyl groups, naphthyl groups, or 5-10 membered heteroaryl groups, preferably R １ Each is independently selected from -H, R ２ These are hydrogen, halogen, and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, preferably R ２ Each is independently selected from -H, R Ｓ１ These are halogen and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -C １～３ Alkylene group -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ , -C １～３ Alkylene group - NH ２ -OH, -O(C) １～３ Alkyl alkyl group), -C １～３ Alkylene group -OH, -O (3-7 membered cycloalkyl group), -SH, -S (C １～３ Alkyl alkyl group), -C １～３ Alkylene group -SH, -C(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl alkyl group) C (=O) (C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O)(C) １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, preferably R Ｓ１ These are, independently, halogens or halogenated carbon atoms. １～３ Selected from alkyl groups, more preferably R Ｓ１ These are independently -F, -Br, -Cl, and -CH ２ F, -CHF ２ , -CF ３ ien-CH ２ CH ２ F, -CH ２ CHF ２ ien-CH ２ CF ３ yan-CHFCH ３ or -CF ２ CH ３ Selected from, and more preferably R Ｓ１ These are independently -Cl or -CF ３ Selected from, n １ n is selected from 0, 1, or 2, preferably n １ It is selected from 1, Ring B is selected from a benzene ring or a 5- to 10-membered heteroaromatic ring containing 1, 2, 3, 4, 5, or 6 heteroatoms selected from N, O, or S, preferably, ring B is selected from a benzene ring, a 5-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S, a 6-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S, a 9-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S, or a 10-membered heteroaromatic ring containing 1, 2, or 3 heteroatoms selected from N, O, or S, more preferably, ring B is 【Chemistry 108】 Selected from, R Ｓ２ These are halogen and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, one or more (one or more -O(C) １～３ -O(C) substituted with alkyl group １～３ -C substituted with an alkyl group １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -C １～３ Alkylene group -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ , -C １～３ Alkylene group - NH ２ -OH, -O(C) １～３ Alkyl alkyl group), -C １～３ Alkylene group -OH, -O (3-7 membered cycloalkyl group), -SH, -S (C １～３ Alkyl alkyl group), -C １～３ Alkylene group -SH, -C(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl alkyl group) C (=O) (C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O)(C) １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, preferably R Ｓ２ These are halogen and -C, respectively, independently. １～３ Alkyl alkyl group, -OH, -O(C) １～３ (Alkyl alkyl group) or -C １～３ Selected from alkylene groups -OH, more preferably R Ｓ２ These are independently -F, -Br, -Cl, and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ ien-CH ２ -OH, -CH ２ CH ２ -OH, -OH, -O-CH ３ , -O-CH ２ CH ３ , -O-CH ２ CH ２ CH ３ or -O-CH(CH ３ ) ２ Selected from, and more preferably R Ｓ２ These are independently -F, -Cl, and -CH ３ ien-CH ２ CH ２ Selected from OH or -OH, n ２ n is selected from 0, 1, or 2, preferably n ２ It is selected from 1, R ４ and R ５ This is the same as the definition in claim 59. A compound represented by formula (I) according to any one of claims 1 to 59, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

63. The aforementioned compound is selected from formula (III), 【Chemistry 109】 R Ｙ１３ These are independently -H or -C １～３ Selected from alkyl groups, preferably R Ｙ１３ These are independently -H and -CH ３ ien-CH ２ CH ３ or -CH(CH ３ ) ２ Selected from, more preferably, R Ｙ１３ Each is independently selected from -H, R ３ Halogen, -NH ２ , -Y ２ ~R ７ Selected from, Y ２ is **-C(=O)-NR Ｙ２３ -, **-C(=O)-O-, **-NR Ｙ２３ -C(=O)-, **-NR Ｙ２３ -S(=O)2-, **-S(=O) ２ -NR Ｙ２３ -, **- (C １～６ (Alkylene group) - Y ３ - or **-R Ｙ２１ C=CR Ｙ２１ - Selected from, ** is the base 【Chemical 110】 It shows the connection point with, R Ｙ２３ or R Ｙ２１ These are hydrogen and -C, respectively, independently. １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, -C １～６ Alkoxy group, halogenated C １～６ Alkyl alkyl groups, halogenated C １～６ Selected from an alkoxy group, a 3-14 membered carbon ring group, a 3-14 membered heterocyclic group, a 6-14 membered aryl group, or a 5-14 membered heteroaryl group, preferably R Ｙ２３ or R Ｙ２１ Each time it appears, hydrogen, -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Selected from an alkoxy group, a 3-7 membered carbon ring group, a 3-7 membered heterocyclic group, a phenyl group, a naphthyl group, or a 5-10 membered heteroaryl group, more preferably R Ｙ２３ or R Ｙ２１ Each time it appears, -H, -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 111】 -CH ２ F、-CHF ２ 、-CF ３ 、-CH ２ CH ２ F、-CH ２ CHF ２ 、-CH ２ CF ３ 、-CHFCH ３ 、-CF ２ CH ３ 、-CH ３ -O-CH ３ 、-CH ２ CH ３ -O-CH ３ 、-CH ３ -O-CH ２ CH ３ 、-CH(CH ３ )-O-CH ３ 、 【Chemistry 112】 Selected from, and more preferably R Ｙ２３ or R Ｙ２１ Each time it appears, -H, -CH ３ or -CH ２ CH ３ Selected from, Y ３ teeth, & -C(=O)-NR Ｙ３３ - & -C(=O)-O-, & -NR Ｙ３３ -C (=O)-, & -NR Ｙ３３ -S (=O)-, & -S(=O)-NR Ｙ３３ - & -NR Ｙ３３ -S (=O) ２ - & -S (=O) ２ -NR Ｙ３３ - Selected from, & is, base**-(C １～６ It shows a bonding site with an alkylene group, R Ｙ３３ These are independently -H or -C １～３ Selected from alkyl groups, preferably R Ｙ３３ Each is independently selected from -H, R １ These are hydrogen, halogen, and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl group, -C １～３ Alkoxy group, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, phenyl groups, naphthyl groups, or 5-10 membered heteroaryl groups, preferably R １ Each is independently selected from -H, R ２ These are hydrogen, halogen, and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ -OH, -O(C) １～３ Alkyl(alkyl group), -SH, -S(C １～３ Alkyl alkyl group), -C (=O) (C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, preferably R ２ Each is independently selected from -H, R Ｓ１ These are halogen and -C, respectively, independently. １～３ Alkyl alkyl groups, halogenated C １～３ Alkyl alkyl groups, halogenated C １～３ Alkoxy group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl group, -CN, -C １～３ Alkylene group -CN, -NH ２ ,-NH(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl group) ２ , -C １～３ Alkylene group - NH ２ -OH, -O(C) １～３ Alkyl alkyl group), -C １～３ Alkylene group -OH, -O (3-7 membered cycloalkyl group), -SH, -S (C １～３ Alkyl alkyl group), -C １～３ Alkylene group -SH, -C(=O)(C １～３ Alkyl alkyl group), -S (=O) (C １～３ Alkyl(alkyl group), -S (=O) ２ (C １～３ Alkyl alkyl group), -C(=O)OH, -C(=O)(OC １～３ Alkyl alkyl group), -OC (=O)(C １～３ Alkyl alkyl group), -C(=O)NH ２ , -C(=O)NH(C １～３ Alkyl alkyl group), -C(=O)N(C １～３ (Alkyl group) ２ , -NHC(=O)(C １～３ Alkyl alkyl group), -N(C １～３ (Alkyl alkyl group) C (=O) (C １～３ Alkyl(alkyl group), -S(=O)NH ２ , -S(=O)NH(C １～３ Alkyl(alkyl group), -S(=O)N(C) １～３ (Alkyl group) ２ , -NHS(=O)(C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O)(C) １～３ Alkyl(alkyl group), -S (=O) ２ NH ２ , -S (=O) ２ NH(C) １～３ Alkyl(alkyl group), -S (=O) ２ N(C) １～３ (Alkyl group) ２ , -NHS (=O) ２ (C １～３ Alkyl alkyl group), -N(C １～３ Alkyl(S)(=O) ２ (C １～３ Selected from alkyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups, preferably R Ｓ１ These are, independently, halogens or halogenated carbon atoms. １～３ Selected from alkyl groups, more preferably R Ｓ１ These are independently -F, -Br, -Cl, and -CH ２ F, -CHF ２ , -CF ３ ien-CH ２ CH ２ F, -CH ２ CHF ２ ien-CH ２ CF ３ yan-CHFCH ３ or -CF ２ CH ３ Selected from, and more preferably R Ｓ１ These are independently -Cl or -CF ３ Selected from, n １ n is selected from 0, 1, or 2, preferably n １ It is selected from 1, R ７ is -H, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Selected from an alkynyl group, a 3-7 membered carbon ring group, a 3-7 membered heterocyclic group containing a heteroatom selected from 1, 2, or 3 N, O, or S, a 6-10 membered aryl group, or a 5-10 membered heteroaryl group containing a heteroatom selected from 1, 2, or 3 N, O, or S, and the -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, 3-7 membered carbon ring group, 3-7 membered heterocyclic group, 6-10 membered aryl group, or 5-10 membered heteroaryl group, one or more R ９ It may also be replaced with R ９ is halogen, -C １～４ Alkyl alkyl group, -CN, -C(=O)(OC １～４ Alkyl alkyl group), -Si (C １～３ (Alkyl group) ３ , selected from phenyl groups, the R ９ is one or more R ９Ａ It may also be replaced with The aforementioned R ９Ａ is halogen, halogenated C １～３ Alkyl or -C １～３ Selected from alkoxy groups, n ５ n is selected from 0, 1, or 2, preferably n ５ It is selected from 0. R Ｙ１３ , R Ｓ２ , R ４ and R ５ This is the same as the definition in claim 58. A compound represented by formula (I) according to any one of claims 1 to 58, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

64. R ７ These are independently -H and -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Selected from an alkynyl group, a 3-7 membered cycloalkyl group, a 3-7 membered heterocyclic group, a 6-10 membered aryl group, or a 5-10 membered heteroaryl group, the -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl group, -C ２～３ Alkynyl groups, 3-7 membered cycloalkyl groups, 3-7 membered heterocyclic groups, 6-10 membered aryl groups, or 5-10 membered heteroaryl groups are halogens, -C １～３ Alkyl alkyl group, -CN, -C(=O)(OC １～４ Alkyl alkyl group), -Si (C １～３ (Alkyl group) ３ Or one, two, or three halogenated carbon atoms １～３ It may be substituted with 0, 1, 2, or 3 substituents selected from a 6- to 10-membered aryl group, which may also be substituted with substituents selected from alkyl groups. Preferably, R ７ These are independently -H and -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 113】 Tetrahydropyranyl group, piperidinyl group, 【Chemistry 114】 Selected from a furyl group, thienyl group, pyridyl group, pyrimidyl group, pyridazyl group, pyrazinyl group, pyrrolyl group, imidazolyl group, pyrazolyl group, thiazolyl group, isothiazolyl group, oxazolyl group, isoxazolyl group or benzothiazolyl group, the R ７ -F, -Cl, -Br, -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , -CN, -C(=O)(OCH ３ ), -C(=O)(OCH ２ CH ３ ), -C(=O)(OCH ２ CH ２ CH ３ ), -C(=O)(OCH(CH ３ ) ２ ), -C(=O)(OC(CH ３ ) ３ ), -Si(CH ３ ) ３ , -Si(CH ２ CH ３ ) ３ , -Si(CH(CH ３ ) ２ ) ３ , 【Chemical 115】 1, 2, or 3 -CH ２ F, -CHF ２ , -CF ３ ien-CH ２ CH ２ F, -CH ２ CHF ２ ien-CH ２ CF ３ yan-CHFCH ３ or -CF ２ CH ３ Substituting with a substituent selected from may be used 【Chemistry 116】 It may be substituted with 0, 1, 2, or 3 substituents selected from the following: More specifically, R ７ These are independently -H and -CH ３ ien-CH ２ CH ３ , 【Chemistry 117】 Tetrahydropyranyl group, piperidinyl group, 【Chemistry 118】 The group R7 is selected from furyl, pyrrolyl, pyridyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, and benzothiazolyl groups, and R7 is -Cl, -Br, or -CH ３ , -CN, -C(=O)(OCH ２ CH ３ ), -C(=O)(OC(CH ３ ) ３ ), -Si(CH(CH ３ ) ２ ) ３ or 【Chemical 119】 It may be substituted with 0, 1, 2, or 3 substituents selected from the above. A compound represented by formula (III) as described in claim 63, its stereoisomer, its tautomer, its atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer or a pharmaceutically acceptable salt of its atropisomer.

65. R ７ は、-H、-CH ３ 、-CH ２ CH ３ 、 【Chemical 120】 Selected from, A compound represented by formula (I) according to any one of claims 63 to 64, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

66. The aforementioned compound is selected from formula (III-1), 【Chemistry 121】 R Ｙ２３ Each occurrence of -H or -C １～３ It is an alkyl group, preferably R Ｙ２３ These are independently -H or -CH ３ Selected from, R ７ is -H, -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Selected from an alkynyl group, a 3-7 membered carbon ring group, a 3-7 membered heterocyclic group containing a heteroatom selected from 1, 2, or 3 N, O, or S, a 6-10 membered aryl group, or a 5-10 membered heteroaryl group containing a heteroatom selected from 1, 2, or 3 N, O, or S, and the -C １～６ Alkyl alkyl group, -C ２～６ Alkenyl group, -C ２～６ Alkynyl group, 3-7 membered carbon ring group, 3-7 membered heterocyclic group, 6-10 membered aryl group, or 5-10 membered heteroaryl group, one or more R ９ It may also be replaced with R ９ is halogen, -C １～４ Alkyl alkyl group, -CN, -C(=O)(OC １～４ Selected from alkyl groups and phenyl groups, the R ９ is one or more R ９Ａ It may also be replaced with The aforementioned R ９Ａ C is a halogenated C １～３ Selected from alkyl groups, R Ｙ１３ , R １ , R ２ , R ４ , R ５ , R Ｓ１ , n １ , R Ｓ２ and n ５ This is the same as the definition in claim 63. A compound represented by formula (I) according to any one of claims 63 to 65, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

67. R ７ is, -C １～３ Alkyl alkyl group, -C ２～３ Selected from an alkenyl group, a 3-7 membered carbon ring group, a 3-7 membered heterocyclic group containing one, two, or three heteroatoms selected from N, O, or S, or a 5-6 membered heteroaryl group containing one, two, or three heteroatoms selected from N, O, or S, the -C １～３ Alkyl alkyl group, -C ２～３ Alkenyl groups, 3- to 7-membered carbon ring groups, 3- to 7-membered heterocyclic groups, or 5- to 6-membered heteroaryl groups have 0, 1, 2, or 3 R ８ It may be replaced by the above R ８ is, -C １～３ Alkyl alkyl group, -CN, -C(=O)(OC １～４ Alkyl group), 1, 2, or 3 halogenated C １～３ A phenyl group may be substituted with a substituent selected from alkyl groups, Preferably, R ７ These are independently -H and -CH ３ ien-CH ２ CH ３ , 【Chemistry 122】 Selected from tetrahydropyranyl group, piperidinyl group, furyl group, pyrrolyl group, pyridyl group, imidazolyl group, pyrazolyl group, thiazolyl group, isothiazolyl group, oxazolyl group or isoxazolyl group, the R ７ This includes 0, 1, 2, or 3 -CH ３ , -CN, -C(=O)(OC(CH ３ ) ３ )or 【Chemical 123】 They may be substituted with substituents selected from A compound represented by formula (I) according to claim 66, its stereoisomer, its tautomer, its atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer or a pharmaceutically acceptable salt of its atropisomer.

68. R ７ is, -CH ３ , 【Chemistry 124】 Selected from, A compound represented by formula (III-1) according to any one of claims 66 to 67, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

69. base 【Chemistry 125】 teeth, 【Chemistry 126】 Selected from, A compound represented by formula (III-1) according to any one of claims 66 to 68, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

70. The aforementioned compound is selected from formula (III-2), 【Chemistry 127】 R Ｙ２３ Each occurrence of -H or -C １～３ It is an alkyl group, preferably R Ｙ２３ These are independently -H or -CH ３ Selected from, R ７ is -H, -C １～６ Selected from alkyl groups, 3- to 7-membered carbon ring groups, phenyl groups, or 5- to 10-membered heteroaryl groups containing heteroatoms selected from 1, 2, or 3 N, O, or S, and the -C １～６ Alkyl groups, 3- to 7-membered carbon ring groups, phenyl groups, or 5- to 10-membered heteroaryl groups are one or more R ９ It may also be replaced with R ９ is halogen or -C １～３ Selected from alkyl groups, R Ｙ１３ , R １ , R ２ , R ４ , R ５ , R Ｓ１ , n １ , R Ｓ２ and n ５ This is the same as the definition in claim 63. A compound represented by formula (I) according to any one of claims 63 to 65, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

71. R ７ is -H, -C １～３ Selected from alkyl groups, 3- to 7-membered carbon ring groups, phenyl groups, or 5- to 6-membered heteroaryl groups containing heteroatoms selected from 1, 2, or 3 N, O, or S, and the -C １～３ Alkyl groups, 3- to 7-membered carbon ring groups, phenyl groups, or 5- to 6-membered heteroaryl groups may have 0, 1, 2, or 3 halogens or -C １～３ It may be substituted with an alkyl group. Preferably, R ７ is -H, -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ , 【Chemistry 128】 Selected from a phenyl group, a pyridyl group, and a benzothiazolyl group, the R ７ This includes 0, 1, 2, or 3 -F, -Br, -Cl, -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ They may be substituted with substituents selected from A compound represented by formula (III-2) as described in claim 70, its stereoisomer, its tautomer, its atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer or a pharmaceutically acceptable salt of its atropisomer.

72. R ７ is, -CH ３ ien-CH ２ CH ３ , 【Chemistry 129】 Selected from, A compound represented by formula (III-2) according to any one of claims 70 to 71, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

73. base 【Chemistry 130】 teeth, 【Chemistry 131】 Selected from, A compound represented by formula (III-2) according to any one of claims 70 to 72, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

74. The aforementioned compound is selected from formula (III-3), 【Chemistry 132】 R Ｙ２３ Each occurrence of -H or -C １～３ It is an alkyl group, preferably R Ｙ２３ Each is independently selected from -H, R ７ The group is selected from a phenyl group or a 5-6 membered heteroaryl group, and the phenyl group or 5-6 membered heteroaryl group has 0, 1, 2 or 3 -C atoms. １～３ It may be substituted with a substituent selected from alkyl groups. R １ , R ２ , R ４ , R ５ , R Ｓ１ , n １ , R Ｓ２ and n ５ This is the same as the definition in claim 63. A compound represented by formula (I) according to any one of claims 63 to 65, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

75. R ７ The group is selected from a phenyl group, a pyridyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, or an isoxazolyl group, and the R ７ This includes 0, 1, 2, or 3 -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ or -CH(CH ３ ) ２ They may be substituted with substituents selected from A compound represented by formula (III-3) as described in claim 74, its stereoisomer, its tautomer, its atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer or a pharmaceutically acceptable salt of its atropisomer.

76. R ７ teeth, 【Chemistry 133】 Selected from, A compound represented by formula (III-3) according to any one of claims 74 to 75, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

77. base 【Chemistry 134】 teeth, 【Chemistry 135】 Selected from, A compound represented by formula (III-3) according to any one of claims 74 to 76, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

78. The aforementioned compound is selected from formula (III-4), 【Transformation 136】 Y ３ teeth, & -C(=O)-NR Ｙ３３ -or & -C(=O)-O- is selected, & is the base (C １～６ It shows the bonding site with the alkylene group. R Ｙ３３ These are independently -H or -C １～３ Selected from alkyl groups, preferably R Ｙ３３ These are independently -H or -CH ３ Selected from, R ７ is hydrogen, -C １～３ Selected from alkyl groups or 5-10 member heteroaryl groups, the -C １～３ The alkyl group or 5-10 membered heteroaryl group is one or more -C １～３ It may be substituted with a substituent selected from alkyl groups. R １ , R ２ , R ４ , R ５ , R Ｓ１ , n １ , R Ｓ２ and n ５ This is the same as the definition in claim 63. A compound represented by formula (I) according to any one of claims 63 to 65, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

79. The aforementioned compound is selected from formula (III-5), 【Chemistry 137】 Y ３ teeth, & -C(=O)-NH-, & -C(=O)-N(CH ３ )-or & -C(=O)-O- is selected, & The group is - (CH ２ )n １２ Shows the connection point with ~, n １２ is selected from 1, 2, 3, 4, 5 or 6, preferably n １２ is selected from 1, 2, or 3, and more preferably n １２ This is selected from 1 or 2. Y ３ , R ７ , R １ , R ２ , R ４ , R ５ , R Ｓ１ , n １ , R Ｓ２ and n ５ This is the same as the definition in claim 78. A compound represented by formula (III-4) as described in claim 78, its stereoisomer, its tautomer, its atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of its stereoisomer, a pharmaceutically acceptable salt of its tautomer or a pharmaceutically acceptable salt of its atropisomer.

80. The aforementioned compound is selected from formula (III-5-1) or formula (III-5-2), 【Chemistry 138】 n １２ This is selected from 1 or 2. R ７ , R １ , R ２ , R ４ , R ５ , R Ｓ１ , n １ , R Ｓ２ and n ５ This is the same as the definition in claim 78. A compound of formula (III-4) according to any one of claims 78 to 79, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

81. R ７ is -H, -CH ３ ien-CH ２ CH ３ ien-CH ２ CH ２ CH ３ , -CH(CH ３ ) ２ Selected from a pyridyl group, a thiazolyl group, and an isoxazolyl group, the R ７ This is 0, 1, or 2 -CH ３ They may be substituted with substituents selected from A compound of formula (III-4) according to any one of claims 78 to 80, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

82. R ７ は、-H、-CH ３ 、-CH ２ CH ３ ,-EH(EH ３ ) ２ 、-C(CH ３ ) ３ 、 【Chemistry 139】 Selected from, A compound of formula (III-4) according to any one of claims 78 to 81, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

83. base [Chemical 140] teeth, 【Chemistry 141】 Selected from, A compound represented by formula (III-4) according to any one of claims 78 to 82, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

84. The aforementioned compound is one of the following formulas: 【Chemistry 142】 【Chemistry 143】 【Chemistry 144】 【Chemistry 145】 【Chemistry 146】 A compound represented by formula (I) according to any one of claims 1 to 83, a stereoisomer thereof, a tautomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, a pharmaceutically acceptable salt of a tautomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof.

85. A pharmaceutical composition comprising a compound according to any one of claims 1 to 84, a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof or a pharmaceutically acceptable salt of its atropisomer, and at least one pharmaceutically acceptable excipient.

86. A method for treating an individual suffering from cancer related to fascin overexpression, comprising administering to the individual a therapeutically effective amount of a compound according to any one of claims 1 to 84, its stereoisomer, its atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of its stereoisomer or a pharmaceutically acceptable salt of its atropisomer, or a pharmaceutical composition according to claim 85. Preferably, the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, upper respiratory tract and gastrointestinal cancer, colorectal cancer, urinary tract cancer, or colon cancer. More preferably, each type of cancer is independently selected from adenocarcinoma, squamous cell carcinoma, adenosquamous mixed carcinoma, or undifferentiated carcinoma. More preferably, the ovarian cancer includes high-grade ovarian adenocarcinoma, ovarian mucinous cystadenocarcinoma, or malignant ovarian Brenner tumor. The kidney cancer includes clear cell renal cell carcinoma. The tongue cancer includes squamous cell carcinoma of the tongue. The method includes, "lung cancer" including lung adenocarcinoma, lung adenosquamous carcinoma, squamous cell lung cancer, large cell lung cancer, small cell lung cancer, papillary adenocarcinoma of the lung, or non-small cell lung cancer; "pancreatic cancer" including pancreatic adenocarcinoma or pancreatic ductal adenocarcinoma; "esophageal cancer" including esophageal squamous cell carcinoma; "mesothelioma" including biphasic mesothelioma; "central nervous system cancer" including glioma, glioblastoma, or glioblastoma multiforme; "gastric cancer" including gastric adenocarcinoma; "breast cancer" including ductal carcinoma, mammary gland carcinoma, or HR+ breast cancer; "bladder cancer" including bladder squamous cell carcinoma; "melanoma" including malignant melanoma; "colon cancer" including colon adenocarcinoma; and "head and neck cancer" including head and neck small cell squamous cell carcinoma.

87. Preferably, the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, upper respiratory tract and gastrointestinal cancer, colorectal cancer, urinary tract cancer, or colon cancer. More preferably, each type of cancer is independently selected from adenocarcinoma, squamous cell carcinoma, mixed adenosquamous carcinoma, or undifferentiated carcinoma. More preferably, the ovarian cancer includes high-grade ovarian adenocarcinoma, ovarian mucinous cystadenocarcinoma, or malignant ovarian Brenner tumor. The kidney cancer includes clear cell renal cell carcinoma. The tongue cancer includes squamous cell carcinoma of the tongue. The lung cancer includes lung adenocarcinoma, lung adenosquamous carcinoma, squamous cell lung cancer, large cell lung cancer, small cell lung cancer, papillary adenocarcinoma of the lung, or non-small cell lung cancer; the pancreatic cancer includes pancreatic adenocarcinoma or pancreatic ductal adenocarcinoma; the esophageal cancer includes esophageal squamous cell carcinoma; the mesothelioma includes biphasic mesothelioma; the central nervous system cancer includes glioma, glioblastoma, or glioblastoma multiforme; the gastric cancer includes gastric adenocarcinoma; the breast cancer includes ductal carcinoma, mammary gland carcinoma, or HR+ breast cancer; the bladder cancer includes bladder squamous cell carcinoma; the melanoma includes malignant melanoma; the colon cancer includes colon adenocarcinoma; and the head and neck cancer includes head and neck small cell squamous cell carcinoma. Use of a compound according to any one of claims 1 to 84, its stereoisomer, its atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of its stereoisomer or a pharmaceutically acceptable salt of its atropisomer, or a pharmaceutical composition according to claim 85, in the preparation of a drug for treating cancer related to fascin overexpression.

88. It is used to treat cancers related to fascin overexpression. Preferably, the cancer is selected from breast cancer, central nervous system cancer, endometrial cancer, kidney cancer, colorectal cancer, lung cancer, esophageal cancer, tongue cancer, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, mesothelioma, melanoma, fibrosarcoma, bladder cancer, rectal cancer, lymphoma, cervical cancer, head and neck cancer, upper respiratory tract and gastrointestinal cancer, colorectal cancer, urinary tract cancer, or colon cancer. More preferably, each type of cancer is independently selected from adenocarcinoma, squamous cell carcinoma, mixed adenosquamous carcinoma, or undifferentiated carcinoma. More preferably, the ovarian cancer includes high-grade ovarian adenocarcinoma, ovarian mucinous cystadenocarcinoma, or malignant ovarian Brenner tumor. The kidney cancer includes clear cell renal cell carcinoma. The tongue cancer includes squamous cell carcinoma of the tongue. The lung cancer includes lung adenocarcinoma, lung adenosquamous carcinoma, squamous cell lung cancer, large cell lung cancer, small cell lung cancer, papillary adenocarcinoma of the lung, or non-small cell lung cancer; the pancreatic cancer includes pancreatic adenocarcinoma or pancreatic ductal adenocarcinoma; the esophageal cancer includes esophageal squamous cell carcinoma; the mesothelioma includes biphasic mesothelioma; the central nervous system cancer includes glioma, glioblastoma, or glioblastoma multiforme; the gastric cancer includes gastric adenocarcinoma; the breast cancer includes ductal carcinoma, mammary gland carcinoma, or HR+ breast cancer; the bladder cancer includes bladder squamous cell carcinoma; the melanoma includes malignant melanoma; the colon cancer includes colon adenocarcinoma; and the head and neck cancer includes head and neck small cell squamous cell carcinoma. A compound according to any one of claims 1 to 84, a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof, or a pharmaceutical composition according to claim 85.